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ABSTRACT 
 
Background and purpose: Merkel cell carcinoma (MCC) is a rare and often aggressive 
skin cancer that usually arises in elderly individuals. MCC is frequently associated with 
ultraviolet radiation exposure and immunosuppressive conditions. The majority of MCCs 
harbor Merkel cell polyomavirus (MCPyV), a newly discovered human cancer virus. Several 
studies have indicated its importance in MCC tumorigenesis.  
 
The  aim  of  the  thesis  was  to  evaluate  the  frequency  of  MCPyV  infection  in  MCC  and  to  
investigate its associations with patient and tumor characteristics, and with survival. In 
addition, we aimed to investigate the associations between MCPyV infection with cell cycle 
regulatory protein expression, platelet-derived growth factor receptor (PDGFR) family 
protein expression, TP53, KIT and PDGFRA mutations, and their associations with 
clinicopathological factors. We also determined the frequency and type of leukocytes that 
infiltrate MCC, and their associations with the presence of MCPyV DNA in MCC and 
clinicopathological factors including disease outcome. 
 
Experimental design: The study was based on a population-wide MCC patient series from 
Finland, with the MCCs diagnosed in 1979 to 2004, and the corresponding archival formalin-
fixed paraffin-embedded tumor tissue samples. The patients were identified from the files of 
the Finnish Cancer Registry. MCPyV DNA was detected using polymerase chain reaction 
(PCR) and quantitative PCR, tumor infiltrating immune cells were identified and the 
expression of MCPyV large T (LT) antigen and other proteins was assessed by 
immunohistochemistry. Gene mutations were investigated using PCR and DNA sequencing. 
Protein expression was usually assessed from tissue microarray (TMA) sections, while the 
numbers of tumor infiltrating leukocytes were counted from full tumor tissue sections. The 
associations between the molecular and host response factors studied and the 
clinicopathological factors including survival were investigated using conventional statistical 
tests, such as Kaplan-Meier survival analyses and Cox’s proportional hazards models. 
 
9 
 
Results:  We found that most (approximately 80%) MCCs harbor MCPyV DNA and that the 
MCPyV LT antigen was expressed in 67% of the tumors. The presence of MCPyV DNA in 
tumor was associated with better disease-specific (5-year survival: 75.9% vs. 41.1%, p < 
0.001) and overall survival (5-year survival: 45.0% vs. 13.0%, p < 0.001) as compared to 
MCPyV-negative MCCs. The MCPyV DNA-positive MCCs were located more often in a limb 
than in a trunk or head and neck region, they had less often metastasized to regional lymph 
nodes at the time of the diagnosis, and less often expressed p53 and KIT than MCPyV-
negative tumors (p-values < 0.05). LT antigen expression in tumor cells was associated with 
the female gender, location of the tumor in a limb, low cell proliferation rate, and absence of 
p53 expression in tumor (p-values < 0.05). Retinoblastoma protein (RB) expression was 
almost invariably associated with presence of MCPyV DNA and LT expression in MCC (p-
values < 0.0001), whereas TP53 mutations were found exclusively in MCPyV-negative 
tumors (p=0.001). The presence of MCPyV DNA and LT antigen expression in tumor were 
independent prognostic factors for favorable overall survival in a Cox multivariable analysis, 
when gender and the nodal status, or the post-surgical stage were included as covariables in 
the analyses. 
 
No KIT or PDGFRA mutations were found in MCC. Tumors with p53 expression were 
associated with worse MCC-specific and overall survival as compared to p53-negative 
tumors, whereas tumor RB expression was associated with favorable survival. MCPyV DNA-
positive MCCs contained significantly higher numbers of tumor infiltrating CD3+, CD8+, 
CD16+, FoxP3+, and CD68+ cells in comparison to MCPyV DNA-negative MCCs. A higher 
than the median number of CD3+, CD8+ and FoxP3+ T lymphocytes, and high CD8+/CD4+ 
and FoxP3+/CD4+ cell ratios in tumor were associated with favorable overall survival. Both 
a higher than the median number of intratumoral CD3+ cells and the presence of MCPyV 
DNA in tumor were independently associated with favorable overall survival in a Cox 
multivariable analysis that included also the nodal status and gender as covariables. 
 
Conclusions: MCPyV-positive and -negative MCCs differ in molecular features. They show 
important differences also in their clinical outcomes and associations with several 
clinicopathological factors, as well as in host immune response. A high number of tumor 
infiltrating T lymphocytes and presence of MCPyV DNA in tumor were identified as novel 
independent prognostic factors in MCC.  
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REVIEW OF THE LITERATURE 
 
1. Merkel cell carcinoma 
 
Merkel cells are neuroendocrine cells of the skin that are essential for generation of light-
touch responses (Maricich et al. 2009). They differentiate from the epidermal progenitor 
cells during the embryonic development. In adults, Merkel cells are replaced from the 
epidermal stem cells and not from differentiated Merkel cells (Van Keymeulen et al. 2009). 
In 1972 Toker introduced for the first time the term “trabecular carcinoma of the skin” to 
describe a malignant skin cancer that is now known as Merkel cell carcinoma (MCC) (Toker 
1972). Six years later Tang and Toker suggested that trabecular carcinoma of skin is derived 
from cells of the neural crest origin, probably from Merkel cells, due to the close structural 
similarities found between the Merkel cells and MCC cells in electron microscopic analyses 
(Tang, Toker 1978). The demonstration that Merkel cells differentiate from the epidermal 
stem cells (Van Keymeulen et al. 2009), rare basal cell carcinoma progression to MCC (Patel, 
Adsay & Andea 2010) and co-existence of MCC, basal cell and squamous cell carcinomas in 
the same skin lesion (Cerroni, Kerl 1997), and several studies that report MCCs with 
squamous or sarcomatous differentiation (Walsh 2001, Hwang et al. 2008, Cooper et al. 
2000), favor the hypothesis that MCC has a stem cell origin. 
 
1.1 Epidemiology 
 
MCC is a rare cancer that usually manifests in elderly white people. In the National Cancer 
Data Base of the United States, consisting of 10,020 patients diagnosed with MCC from 1986 
to  2004,  the majority  (96.2%) of  MCC patients  were found to  be  white,  whereas  only  1.3% 
were African American and 2.5% belonged to other races (Lemos et al. 2010). Men were 
reported to be more frequently affected than females in Scotland (Mills, Durrani & Watson 
2006), Western Australia (Girschik et al. 2011), the Netherlands (Reichgelt, Visser 2011) and 
the United States (Albores-Saavedra et al. 2010), whereas in Denmark (Kaae et al. 2010) and 
Finland (Kukko et al. 2012) the age-adjusted incidence rate is similar for both genders (Mills, 
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Durrani & Watson 2006, Girschik et al. 2011, Reichgelt, Visser 2011, Albores-Saavedra et al. 
2010, Kaae et al. 2010, Kukko et al. 2012).  
 
The incidence of MCC increases after the age of 60, and the mean and the median age at the 
time of MCC diagnosis is approximately 75 years in several series (Lemos et al. 2010, Mills, 
Durrani & Watson 2006, Girschik et al. 2011, Reichgelt, Visser 2011, Albores-Saavedra et al. 
2010, Kaae et al. 2010, Kukko et al. 2012, Bzhalava et al. 2011, Agelli, Clegg 2003). Only less 
than 4% of the patients are under 50 at the time of the diagnosis (Albores-Saavedra et al. 
2010, Kaae et al. 2010, Kukko et al. 2012).  
 
The reported age-adjusted incidence rates has varied between different populations, being 
the lowest in Finland (1.2 cases per million per annum)(Kukko et al. 2012), followed by 
France (Riou-Gotta et al. 2009), Scotland (Mills, Durrani & Watson 2006), and Denmark 
(Kaae et al. 2010) (1.3 to 2.2 cases per million per year), and the Netherlands (Reichgelt, 
Visser  2011)  and the United States  (3.5  to  4.4)  (Hodgson 2005).  The highest  rate  has  been 
reported form Western Australia (8.2) (Girschik et al. 2011). These aged-adjusted incidence 
rates may not be directly comparable, since different standard populations were used as the 
reference population in these analyses. The annual incidence rate has been reported to 
increase in the Netherlands (Reichgelt, Visser 2011), in the United States (Albores-Saavedra 
et al. 2010), whereas in Australia (Girschik et al. 2011) and the Nordic countries (Kaae et al. 
2010, Kukko et al. 2012) the incidence rate has been relatively stable. A few studies have 
reported an increase in the incidence prior to its stabilization during the last few decades, 
which may in part reflect improved awareness of MCC among clinicians and advances in the 
diagnostic methods (Agelli, Clegg 2003).  
 
1.2 Clinical features 
 
Most of the MCC lesions are asymptomatic and may resemble benign tumors in appearance 
(Heath et al. 2008). In 2008 Heath and colleagues reviewed the tumor characteristics and 
proposed the AEIOU features (Asymptomatic/lack of tenderness, Expanding rapidly, 
Immune suppression, Older than 50 years, and Ultraviolet-exposed site on a person with fair 
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skin) to help the clinicians to recognize a lesion suspicious for MCC that warrants 
performing a biopsy. Heath et al.  found that the majority of MCCs were asymptomatic and 
not tender, appeared on sun-exposed skin areas, the lesions were violaceous, pink or red in 
color, and the tumors typically grew rapidly during a few weeks or months. In addition, 90% 
of the patients were over 50 years old, 98% were white and 8% were immunosuppressed due 
to human immunodeficiency virus (HIV) infection, a solid organ transplant or chronic 
lymphocytic leukemia. Most tumors measured less than 2 cm in diameter. 
 
Approximately 70% to 80% of MCC lesions are located in the head and neck region or in the 
extremities, approximately 10% manifest in the trunk, and less than 1% occur in the genitals 
(Lemos et al. 2010, Girschik et al. 2011, Reichgelt, Visser 2011, Albores-Saavedra et al. 2010, 
Kaae et  al.  2010,  Kukko et  al.  2012,  Heath et  al.  2008).  In  a  Western Australia  cohort,  the  
tumors were located on an extremity or in the head and neck region in 88% of the cases 
(Girschik et al. 2011). MCC may rarely occur at an unusual site such as the parotid gland or 
the oral mucosa (Prabhu, Smitha & Punnya 2010, Ghaderi et al. 2010). Sometimes only 
metastases are found without an identifiable primary tumor; the proportion of such cases is 
reported to vary between 0.8% and 14% of all MCC cases (Reichgelt, Visser 2011, Albores-
Saavedra et al. 2010, Kukko et al. 2012, Heath et al. 2008). MCC metastases with an 
unknown primary tumor are found most often in men and in younger individuals, often 
manifesting in the lymph nodes of the head and neck region (Foote et al. 2011). 
 
A majority of the MCC patients have local disease at presentation. In Australia and Europe 
the disease is local in 71% to 90% and has spread only to the regional lymph nodes in 10% to 
21% of the cases, respectively (Girschik et al. 2011, Reichgelt, Visser 2011, Kaae et al. 2010, 
Kukko et al. 2012), whereas in the Surveillance, Epidemiology, and End Results and the 
National Cancer Data Base databases of the United States these figures are 56% to 66% and 
27%  to  35%,  respectively  (Lemos  et  al.  2010,  Girschik  et  al.  2011,  Reichgelt,  Visser  2011,  
Albores-Saavedra et al. 2010, Kaae et al. 2010, Kukko et al. 2012). The most common sites 
for distant metastases are non-regional lymph nodes (27% to 60%), the skin (28% to 30%), 
the lungs (10% to 23%), the central nervous system (6% to 18%), bone (10% to 15%), and the 
liver (13%) (Medina-Franco et al. 2001, Voog et al. 1999). 
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1.3 Histopathological diagnosis 
 
The diagnosis is confirmed by histopathological assessment of the tumor tissue. In 
hematoxylin & eosin stained tissue sections MCC cells are basophilic (purple-blue), small 
and monomorphic, and usually have a high nucleus-to-cytoplasm ratio. MCC cells have pale 
round or oval-shaped nuclei, which contain finely dispersed chromatin, and nucleoli are 
rarely present. The mitotic rate of the tumor cells is usually high (Bickle et al. 2004).  
 
MCC can be divided into three histological subtypes. The most common subtype, the 
intermediate cell type, displays a solid, diffuse growth pattern (Figure 1, panel A); the small 
cell type resembles small cell lung carcinoma at histological examination and is composed of 
solid sheets of cells and clusters of cells that lack glandular differentiation (panel B); and the 
least common subtype, the trabecular type, contains cells growing in ribbon-like clusters 
and can exhibit gland-like formations (panel C) (Bickle et al. 2004). The tumors are 
frequently necrotic and invade into the subcutaneous adipose tissue, and a dense 
lymphocytic infiltration is often present within and around the tumor (Bickle et al. 2004, 
Mott,  Smoller  & Morgan 2004).  Perineural  (48%) or  vascular  invasion (44% up to  93%) is  
frequent in MCC, albeit the majority (66%) of tumors show only lymphovascular invasion 
(Mott, Smoller & Morgan 2004, Kukko et al. 2010).  
 
Figure 1. The representative figures of histological MCC subtypes; (A) the 
intermediate type, (B) the small cell type, and (C) the trabecular type. 
 
Immunohistochemical stainings are required to confirm the diagnosis and to distinguish 
MCC from other cancers. The World Health Organization (WHO) Classification of Tumors 
recommends using immunostainings to detect cytokeratin 20 (CK20), the thyroid 
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transcription factor-1 (TTF-1), S-100, the leukocyte common antigen and several 
neuroendocrine differentiation markers such as chromogranin, synaptophysin, neuron-
specific enolase and bombesin in the differential diagnosis (Kohler, Kerl 2006). CK20 
positivity and TTF-1 negativity differentiate MCCs effectively from other small cell 
carcinomas (Cheuk et al. 2001). 
 
1.4 Etiology 
 
A causal role of ultraviolet light (UV) exposure is supported by several findings in the 
pathogenesis of MCC. MCC arises frequently in sun-exposed skin areas (Lemos et al. 2010, 
Girschik et al. 2011, Reichgelt, Visser 2011, Albores-Saavedra et al. 2010, Kaae et al. 2010, 
Kukko et al. 2012, Heath et al. 2008). Geographically MCC incidence has been higher in 
areas with high UV-B solar index, being the highest in Australia and the lowest in the Nordic 
countries  and  Scotland  (Mills,  Durrani  &  Watson  2006,  Girschik  et  al.  2011,  Kukko  et  al.  
2012). The incidence rates of MCC correlated with the UV-B index within the U.S., being the 
highest in Hawaii and the lowest in Detroit (Agelli, Clegg 2003). UV-radiation induces 
mutagenesis by damaging DNA, and UV-associated mutations can be found in known tumor 
suppressor genes such as TP53 in cancer (Pfeifer, You & Besaratinia 2005). UV radiation 
induces local immunosuppression on the skin, and a number of different immune cell types 
such as T and B lymphocytes and mast cells are involved in this process (Fisher, Kripke 1982, 
Toda et al. 2011, Krasteva et al. 2002, Byrne, Limon-Flores & Ullrich 2008). MCC patients 
have an increased risk for non-melanoma and melanoma skin cancers before and after the 
diagnosis of MCC (Kaae et al. 2010, Bzhalava et al. 2011, Koljonen et al. 2010, Howard et al. 
2006). UV-exposure may thus be a common risk factor for these skin cancers, and some of 
them may share the epidermal stem cell origin. 
 
Host immunosuppression is also strongly associated with the genesis of MCC. A population-
based  study  from  the  U.S.  found  that  HIV/AIDS  patients  had  an  11-fold  risk  for  MCC  in  
comparison  to  the  general  population  (Lanoy  et  al.  2009).  Patients  with  a  solid  organ  
transplant are also at a higher risk for MCC due to the long-term immunosuppression 
treatments (Koljonen et al. 2009, Buell et al. 2002, Penn, First 1999, Lanoy, Costagliola & 
Engels 2010). Interestingly, both patients with an organ transplant and HIV had the mean 
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age at the time of MCC diagnosis less than 50 years as compared to 75 years in patients 
without one of these risk factors (Buell et al. 2002, Penn, First 1999). Other 
immunosuppressive conditions may also predispose to MCC. In one study, five out of six 
young MCC patients diagnosed at the age of less than 50 had altered immunocompetence 
either due to pregnancy, sarcoidosis or medications such as psoralen administered for UV-A 
treatment of psoriasis (Sahi et al. 2010). 
 
Chronic lymphocytic leukemia (CLL) and some other hematological malignancies are 
associated with MCC (Kaae et al. 2010, Koljonen et al. 2010, Howard et al. 2006, Tadmor et 
al. 2012, Ascoli et al. 2011). Several immune aberrations are linked with CLL, such as B cell 
anergy and hypogammaglobulinemia, decreased T cell responses to mitogens and aberrant T 
cell receptor expression, increased numbers of regulatory T cells and atypical T cell subtype 
ratios, disturbances in natural killer (NK) cell activity, and aberrations in granulocyte and 
monocyte function, cytokine balance and complement levels and activity (Tadmor, Aviv & 
Polliack 2011).  
 
In 2008 Feng and colleagues found a new human polyomavirus, Merkel cell polyomavirus 
(MCPyV, also known as MCV) in 80% of MCCs, and other studies have later confirmed this 
finding  (Feng  et  al.  2008,  Kassem  et  al.  2008,  Garneski  et  al.  2009).  MCPyV  will  be  
discussed more thoroughly in Chapter 2.   
 
1.5 Risk factors for recurrence and death 
 
Men with MCC have a higher risk for death compared to women (Reichgelt, Visser 2011, 
Albores-Saavedra et al. 2010, Kaae et al. 2010, Kukko et al. 2012, Agelli, Clegg 2003). Tumor 
location in the trunk or areas other than the head and neck region is associated with worse 
outcome as compared to the head and neck region (Albores-Saavedra et al. 2010, Agelli, 
Clegg 2003,  Yiengpruksawan et  al.  1991,  Allen,  Zhang & Coit  1999),  although some studies  
have not detected such a survival difference (Girschik et al. 2011, Reichgelt, Visser 2011, Kaae 
et al. 2010, Kukko et al. 2012). Results regarding a potential correlation between high age 
and unfavorable survival have been controversial (Reichgelt, Visser 2011, Albores-Saavedra 
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et al. 2010, Kaae et al. 2010, Kukko et al. 2012, Agelli, Clegg 2003, Foote et al. 2011, Allen et 
al. 2005). Tumor diameter smaller than 2 cm and absence of nodal or distant metastases are 
generally considered to be associated with favorable survival (Lemos et al. 2010, Girschik et 
al. 2011, Reichgelt, Visser 2011, Albores-Saavedra et al. 2010, Kaae et al. 2010, Kukko et al. 
2012, Agelli, Clegg 2003, Allen, Zhang & Coit 1999). Chronic lymphocytic leukemia in history 
has been reported to be an adverse prognostic factor for death (Brewer et al. 2012).  
 
The 5-year MCC-specific or relative survival rates are reported to range from 54% to 75% 
(Girschik et al. 2011, Reichgelt, Visser 2011, Kukko et al. 2012, Agelli, Clegg 2003, Allen et al. 
2005). Several risk factors for MCC-specific survival have been identified. The risk of MCC 
recurrence is increased in patients who have clinically detectable lymph node metastases, the 
tumor shows lymphovascular invasion or the patient has leukemia or lymphoma in history 
(Fields et al. 2011). Presence of histopathologically verified nodal metastases is considered a 
strong prognostic factor for recurrence (Lemos et al. 2010, Allen et al. 2005). It has been 
reported that 23% to 32% of nodal metastases are not detected at clinical examination, 
supporting the importance of pathological examination (Allen et al. 2005, Gupta et al. 
2006). In addition, in a large study consisting of 5823 patients, a pathologically verified 
negative nodal status had significantly better 5-year relative survival compared to patients 
with clinically negative nodal status (76% vs. 59%, p < 0.0001) (Lemos et al.  2010). In one 
study patients presenting with regional nodal metastases (stage III disease) from MCC and 
who had an occult primary tumor had better relapse-free survival compared to patients with 
regional nodal metastases and a known primary tumor (Foote et al. 2011). 
 
Historically, many different staging systems for MCC were used until the American Joint 
Committee on Cancer (AJCC) adopted a new consensus staging system based on a large 
study  of  5823  MCCs  as  proposed  by  Lemos  and  colleagues  (Lemos  et  al.  2010).  In  the  
consensus staging system cancers without pathologically detected nodal metastases or 
clinically detected distant metastases are divided into stage I (diameter ? 2 cm) and stage II 
(diameter > 2 cm), tumors of any size with nodal metastases or with in-transit metastasis 
into stage III, and tumors with distant metastases into stage IV regardless of their size or the 
nodal status (Table 1). 
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Table 1. American Joint Committee on Cancer staging system for Merkel cell 
carcinoma 
Stage Tumor size Regional nodal metastasis Distant 
metastases 
    
0 In situ primary tumor No regional node metastasis No distant 
metastasis 
IA Primary tumor  ? 2 cm Nodes negative in pathologic examination No distant 
metastasis 
IB Primary tumor  ? 2 cm Nodes negative in clinical examination No distant 
metastasis 
IIA Primary tumor  > 2 cm Nodes negative in pathologic examination No distant 
metastasis 
IIB Primary tumor  > 2 cm Nodes negative in clinical examination No distant 
metastasis 
IIC Primary tumor invades bones, 
muscle, fascia, or cartilage  
Nodes negative in clinical and or pathologic 
examination 
No distant 
metastasis 
IIIA Any primary tumor size Micrometastasis diagnosed in sentinel or 
elective lymphadenectomy 
No distant 
metastasis 
IIIB Any primary tumor size Macrometastasis or in-transit metastasis† No distant 
metastasis 
IV Any primary tumor size Any nodal metastasis status Distant 
metastasis 
    
† Clinically detected macrometastasis that is confirmed in pathological examination of 
biopsy or therapeutic lymphadenectomy or in-transit metastasis that is distal to primary 
lesion or is located between primary tumor and draining lymph nodes. 
 
1.6 Treatment and outcome 
 
In the absence of randomized trials, the optimal treatment of MCC is not well known. The 
standard treatment for localized MCC is surgical excision of the primary tumor followed by 
postoperative radiation therapy. Clear surgical margins are associated with a lower risk for 
local  recurrence  as  compared  to  involved  margins  (Kukko  et  al.  2012,  Allen  et  al.  2005).  
Lateral surgical margins of 1-2 cm are usually recommended in surgical treatment protocols, 
and  margins  wider  than  these  (>  2  cm)  may  not  add  any  benefit  (Kukko  et  al.  2012).  As  
compared to patients treated with surgery only, postoperative radiotherapy improved the 
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median 5-year local relapse-free survival (93% vs. 64%, p < 0.001), regional relapse-free 
survival (76% vs. 27%, p < 0.001), distant metastasis-free survival (70% vs. 40%, p=0.01), 
disease-free survival (59% vs. 4%, p<0.001) and MCC-specific survival (65% vs. 49%, 
p=0.03) in patients with local or regional disease in a large retrospective multicenter study 
(Ghadjar et al. 2011). Several other studies have also suggested reduction of the local 
recurrence rate after radiotherapy (Medina-Franco et al. 2001, Gillenwater et al. 2001). 
Some investigators have suggested that locally advanced MCC considered not suitable for 
surgery can be treated with radiotherapy only leading to outcomes similar to those achieved 
with surgery and postoperative radiotherapy (Mortier et al. 2003, Pape et al. 2011).  
 
When sentinel lymph node metastases are found, surgical excision of the primary tumor and 
excision of the involved nodes is recommended followed by locoregional radiotherapy 
(Poulsen 2004). Lymph node dissection has been found to improve relapse-free survival and 
decrease the risk of nodal recurrence (Allen, Zhang & Coit 1999, Allen et al. 2005).  Adjuvant 
chemotherapy has been linked with improved outcome as compared to local therapy only in 
some retrospective studies and has been suggested to be given after surgery and 
radiotherapy (Poulsen 2004). On the other hand, Voog and colleagues concluded after a 
review of the literature that although MCC was chemosensitive, it was not chemocurable, 
and chemotherapy was associated with a risk of severe toxicity (Voog et al. 1999). Patients 
with overt distant metastases may be treated with palliative radiotherapy, chemotherapy or 
surgery.  
 
In an analysis of 2856 MCC patients classified by the consensus staging system, the  5-year 
relative survival rate of patients with primary tumor ?2 cm (T1) and who were node negative 
at clinical examination (cN0, stage Ib) or at pathological examination (pN0, stage Ia) was 
60% and 79%, respectively. The corresponding figures for patients with tumor larger than 2 
cm  in  diameter  (>2  cm  but  ? 5  cm,  T2;  or  >5  cm,  T3)  with  pathologically  negative  nodes  
(T2/3pN0, stage IIb) was 58% and with clinically negative nodes (T2/T3cN0, stage IIb) 49%, 
and the 5-year relative survival rate was 47% when the primary tumor invaded the 
surrounding tissues (T4), but the regional nodes were not involved (stage IIc). Patients with 
micrometastases in the regional lymph nodes or with an unknown regional nodal status 
(stage IIIa) had a 42% 5-year relative survival rate, those with macrometastases in the 
regional nodes (IIIb) 26%, and patients with overtly metastatic disease (M1, stage IV) 18% 
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(Lemos et al. 2010). Another study reported the 5-year relapse-free survival in MCC to be 
48% and the median relapse-free time 9 months (Allen et al. 2005). 
 
2. Merkel cell polyomavirus (MCPyV) 
 
Viruses that belong to the polyomaviridae family are small, non-enveloped icosahedral 
viruses that contain a single, circular and  approximately 5000 base pair (bp) long double-
stranded DNA genome (Johne et al. 2011). Polyomaviruses are widespread in the human 
population. They cause persistent latent infections that are usually asymptomatic, and 
polyomavirus-associated diseases occur mainly after reactivation of the virus in 
immunocompromised inviduals (Delbue, Comar & Ferrante 2012). At present, ten different 
spieces of human polyomaviruses are known (Table 2). The BK polyomavirus (BKPyV) was 
isolated from the urine of a patient with a renal transplant (Gardner et al. 1971), and the JC 
polyomavirus (JCPyV) from the brain of a patient with Hodgkin’s disease and progressive 
multifocal leukoencephalopathy already in 1971 (Padgett et al. 1971). The other seven human 
polyomaviruses were identified recently, the KIPyV and the WUPyV from respiratory track 
samples (Allander et al. 2007, Gaynor et al. 2007), human polyomavirus 6 and 7 (HPyV6 and 
HPyV7)  from  skin  swabs  of  healthy  people  (Schowalter  et  al.  2010),  trichodysplasia 
spinulosa-associated polyomavirus (TSPyV) from papules of the nose of an adolescent heart 
transplant patient diagnosed with trichodysplasia spinulosa (van der Meijden et al. 2010), 
the HPyV9 from the serum of a kidney transplant patient  (Scuda et al.  2011), and HPyV10 
from stool samples of children with diarrhea and from condyloma sample of a patient with 
warts, hypogammaglobulinemia, infections, and myelokathexis syndrome (Siebrasse et al. 
2012, Buck et al. 2012).  
 
MCPyV was the fifth human polyomavirus identified. It was detected from mRNA libraries 
generated from four MCCs using digital transcriptome substraction, a method that enables 
detection of foreign viral transcripts from human high-throughput cDNA sequencing data 
(Feng et al. 2008). The presence of MCPyV DNA in a majority of MCCs was soon verified by 
several  other  studies  (Kassem  et  al.  2008,  Garneski  et  al.  2009,  Becker  et  al.  2009,  
Foulongne et al. 2008). MCPyV turned out to be a ubiquitous virus. Circulating serum IgG 
antibodies against MCPyV has been found in 9% of 1- to 4-year-old children, and their 
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incidence has increased to 80% in people older than 50 (Chen et al. 2011, Tolstov et al. 
2009). Low amounts of MCPyV DNA are detected in the normal human tissues at several 
different body sites, in other skin diseases, and in healthy skin flora (Kantola et al. 2009, 
Foulongne et al. 2010, Loyo et al. 2010). Two studies indicates that the percentage of 
MCPyV-positive MCCs might be lower in Australia than in countries with a lower exposure 
to  UV  radiation  (Garneski  et  al.  2009,  Paik  et  al.  2011),  although  in  one  study  as  many  as  
97% of Australian MCCs were MCPyV-positive (Schrama et al. 2011). 
 
Table 2. Known human polyomaviruses 
   
Virus Time of finding Disease caused by polyomavirus 
BKPyV 1971 BKPyV nephropathy in renal transplant patients 
JCPyV 1971 Progressive multifocal leukoencephalopathy 
KIPyV 2007  
WUPyV 2007  
MCPyV 2008 Merkel cell carcinoma 
HPyV6 2010  
HPyV7 2010  
TSPyV 2010 Thricodylsplasia spinulosa 
HPyV9 2011  
HPyV10 2012  
 
2.1 MCPyV genome, structure and function 
 
In the study where MCPyV was first identified, Feng and colleagues found that MCPyV 
contains a typical circular and approximately 5.4 kbp long polyomavirus genome (Figure 2) 
that showed the highest sequence homology with the African green monkey lymphotropic 
polyomavirus (also known as B-lymphotropic polyomavirus, LPyV)  (Feng et al. 2008). 
MCPyV is known to express the small T antigen (sT), the large T antigen (LT), the 57kT 
antigen and capsid proteins VP1 and VP2, whereas the VP3 capsid protein may not be 
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functional (Shuda et al. 2008, Feng et al. 2011, Pastrana et al. 2009, Shuda et al. 2009). LT, 
57kT and sT antigens are produced from overlapping genes due to alternative splicing 
(Shuda et al. 2008). The MCPyV genome was found to be integrated into the MCC tumor cell 
genome, and eight (80%) out of the ten MCCs investigated contained MCPyV DNA, whereas 
only five (8.5%) out of 59 of tissue samples from various body sites and four (16%) out of the 
25 samples from other skin cancers were MCPyV DNA-positive with only a low viral genome 
copy number (Feng et al. 2008). A phylogenetic analysis of the polyomavirus genome 
sequences indicates that MCPyV, TSPyV and HPyV9 genomes are distinct from other human 
polyomaviruses and that they belong to a branch of a phylogenetic tree that includes also 
several non-human primate polyomaviruses and two murine polyomaviruses (Van Ghelue et 
al. 2012).  
 
Figure 2. The organization of MCPyV genome. 
 
The importance of the 57kT antigen for viral or cellular functions is not yet known, but it 
might be analogous to the simian virus 40 (SV40) 17kT antigen. The 57kT antigen contains 
DnaJ and the retinoblastoma (RB) protein binding domains (Shuda et al. 2008). The SV40 
17kT antigen complements RB binding of the LT antigen, and its DnaJ domain promotes 
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transcription of cyclin A; therefore, it can promote cell cycle progression and cellular 
transformation  (Boyapati  et  al.  2003,  Skoczylas,  Henglein  &  Rundell  2005).  The  57kT  
antigen expression is detectable early after MCPyV genome transfection to human 
embryonic kidney 293 cells, and its splicing might depend on viral DNA replication (Feng et 
al. 2011).  
 
Several molecular mechanisms for the sT and the LT antigen function have already been 
identified. The MCPyV sT antigen contains binding domains for the protein phosphatase 2A 
(PP2A) and DnaJ (Shuda et al. 2008). The promoter of the sT antigen, located in a non-
coding control region of the MCPyV genome, is UV-inducible in vitro and the sT antigen 
transcription is regulated by a UV-dependent manner in the skin, whereas the LT antigen 
expression or the VP1 expression is not affected by the UV light (Mogha et al. 2010). MCPyV 
sT antigen enhances LT antigen-mediated MCPyV replication by targeting PP2A (Feng et al. 
2011,  Kwun  et  al.  2009),  and  its  expression  might  be  required  for  the  production  of  the  
capsid proteins from the late gene region of the genome (Feng et al. 2011). In addition, the sT 
antigen promotes mitogenesis, cell proliferation and cellular transformation by reducing the 
hyperphosphorylated eukaryotic transcription initiation factor 4E-binding protein 1 (4E-
BP1) turnover in a PP2A or DnaJ domain independent manner (Shuda et al. 2011). Its 
inhibition halts the cell cycle progression in MCC cell lines but does not cause cell death 
(Shuda et al. 2011). 
 
The LT antigen contains DnaJ and RB binding domains, a replication origin binding domain, 
an ATPase domain and a helicase domain (Shuda et al. 2008). Several of these LT antigen 
domains function in polyomavirus genome replication (Khopde, Roy & Simmons 2008). The 
DnaJ domain is conserved in polyomaviruses (Khopde, Roy & Simmons 2008) and it is 
essential for viral DNA replication, cellular transformation, transcriptional activation, and 
virion assembly (Chromy, Pipas & Garcea 2003, Sullivan, Pipas 2002, Srinivasan et al. 1997, 
Fewell, Pipas & Brodsky 2002, Campbell et al. 1997). An intact DnaJ region is also required 
for  MCPyV  replication  (Kwun  et  al.  2009).  The  polyomavirus  DnaJ  domain  is  known  to  
recruit and stimulate the heat shock protein 70 (Hsc70), a chaperone protein that induces 
disruption of the RB-E2F complex, and therefore induces E2F driven expression of the genes 
required  for  the  G1  to  S  phase  entry  of  the  cell  cycle  (Srinivasan  et  al.  1997).  The  origin  
binding domain recognizes and binds to the replication origin and induces an unwinding of 
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the double-stranded DNA by the action of helicase domain (Dean et al. 1987, Foster, 
Simmons 2010). DNA unwinding and translocation is powered by the LT ATPase domain 
(Shi  et  al.  2009).  In  addition,  the  SV40  LT  domain  recruits  cellular  proteins  such  as  
topoisomerase I, replication protein A, and DNA polymerase ? that are required for DNA 
replication (Khopde, Roy & Simmons 2008, Braun et al. 1997). 
 
Polyomavirus LT antigens are known to bind also two important tumor cell cycle suppressor 
proteins, p53 and RB (Sullivan, Pipas 2002). The MCPyV LT antigen targets RB, a key 
regulator of the cell cycle G1 to S phase progression, whereas the p53 binding coding region 
is often missing from the mature LT antigen due to MCC-specific mutations in the MCPyV 
genome (Shuda et al. 2008). However, both wild-type and truncated LT antigen are able to 
reduce p53 expression in the UISO MCC cell line with a yet unidentified mechanism 
(Demetriou et al. 2012). A functional LT RB binding domain is required to induce gene 
expressions of survivin, an apoptosis inhibitor protein, and the E2F1 transcription factor and 
cyclin E, promoters of G1 to S phase progression (Arora et al. 2012).  
 
The LT antigen contains also an MCV (MCPyV) T antigen unique region (MUR) adjacent to 
the  RB-binding  site  (Liu  et  al.  2011).  The  MUR  region  binds  to  the  clathrin  heavy  chain  
repeat domain in the hVam6p protein and translocates hVam6p to the nucleus (Liu et al. 
2011). Surprisingly, hVam6p is able to inhibit MCPyV virion production suggesting that it 
may have a role in self-regulatory viral replication repression that might sustain viral latency 
(Feng et al. 2011) Nuclear sequestration inhibits hVam6p-induced lysosomal clustering, and 
has been suggested to contribute also to viral uncoating or virus egress (Liu et al. 2011).  
 
 In addition to viral protein expression, the MCPyV genome encodes MCV-mir-M1-5p, a 
microRNA that is expressed at low levels in 50% of MCPyV-positive MCCs (Seo, Chen & 
Sullivan 2009, Lee et al. 2011). The MCV-mir-M1 sequence shows antisense orientation to 
the LT antigen and likely downregulates LT antigen expression (Lee et al. 2011). Similarly, 
SV40 expresses SV-microRNA that downregulates T antigen expression and CD8 cell 
interferon-? release in late infection, but does not affect the VP protein expression and 
infectious virus assembly. As a consequence of T antigen downregulation, the infected cells 
are less susceptible to lysis induced by CD8 cells (Sullivan et al. 2005). 
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Other predicted targets of MCV-mir-M1 are cellular genes AMBRA1, FOX2, MECP2, 
PIK3CD, PSME3 and RUNX1, which have roles in neural and immune system function, and 
in mRNA splicing (Lee et al. 2011). AMBRA1 has an important role in regulation of 
autophagy and in the nervous system development (Fimia et al. 2007), and a chromatin 
structure regulating protein MeCP2 that is expressed predominantly in neuronal nuclei, may 
have a crucial role in neuronal maintenance (Skene et al. 2010). FOX2 is an alternative exon 
splicing regulator, associated with some cell types and cancer-specific mRNA splicing (Lapuk 
et al. 2010). RUNX1 is a transcription factor that stimulates polyomavirus DNA replication 
and regulates T cell differentiation and function (Murakami et al. 2007, Wong et al. 2011). 
PIK3CD encodes the subunit protein p110? of the PI3K that is important for antigen receptor 
signaling in B and T cells and for cytotoxicity of natural killer cells against cancer cells or 
virally infected cells (Zebedin et al. 2008, Okkenhaug et al. 2002, Guo et al. 2008). PSME3 
encodes a subunit of the immunoproteasome activator PA28 that enhances MHC I class 
antigen processing and epitope presentation in infection (de Graaf et al. 2011). 
 
2.2 MCPyV in tumorigenesis 
 
Several studies indicate that MCPyV is not just a passenger virus but contributes to 
tumorigenesis in the majority of MCCs. Most MCCs contain MCPyV DNA (Feng et al. 2008, 
Kassem  et  al.  2008).  The  MCPyV  DNA  copy  numbers  are  significantly  higher  in  MCC  
samples than in samples from other tissues of healthy or immunocompromised individuals 
(Garneski et al. 2009, Becker et al. 2009, Loyo et al. 2010). The MCPyV genome is clonally 
integrated into the MCC tumor cell genome suggesting that viral integration is an early event 
in MCC tumorigenesis (Feng et al. 2008). The integrated viral genome contains frequently 
MCC-specific truncating mutations that prevent virus replication within the tumor cells 
(Feng et al. 2008, Kassem et al. 2008, Shuda et al. 2008, Laude et al. 2010, Martel-Jantin et 
al. 2012, Schmitt et al. 2012). Like MCPyV, other cancer viruses may become replication 
incompetent by number of different molecular mechanisms (zur Hausen 2008). Viral 
replication incompetence prevents MCPyV reactivation and replication that might prevent 
the host cell survival (Shuda et al. 2008). Mutations may increase the transforming 
properties of MCPyV as with SV40 polyomavirus (zur Hausen 2008, Roberge, Bastin 1988).  
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Houben and colleagues showed that expression of the T antigen is necessary for the growth 
and survival of MCPyV-positive MCC cell lines (Houben et al. 2010). Silencing of T antigen 
expression with exon 1 targeting shRNA caused cell cycle arrest or apoptosis of MCPyV-
positive cell lines, but did not affect a MCPyV-negative cell line (Houben et al. 2010). In a 
subsequent study the same authors found that a silenced T antigen expression by shRNA 
induces MCC regression in a mouse xeno-transplantation model (Houben et al. 2012a). 
Release of RB from the interaction with the T antigen caused accumulation of MCC cells into 
the G1 phase and cell cycle arrest (Houben et al. 2012a). Although the LT antigen targets RB, 
sT antigen expression may also be required for tumor cell proliferation (Shuda et al. 2011). 
Binding  of  RB  by  the  LT  antigen  induces  expression  of  survivin  in  addition  to  cell  cycle  
dysregulation (Arora et al. 2012). Survivin expression is critical for sustained growth of 
MCPyV-positive MCCs, and its selective inhibition by a small-molecule inhibitor YM155 halts 
tumor growth of xenograft MCCs in mice (Arora et al. 2012).  
 
Expression of MCPyV sT antigen induces anchorage- and contact-independent growth in a 
rodent Rat-1 fibroblast cell line, whereas LT antigen expression alone is incapable of cell 
transformation (Shuda et al. 2011). Expression of sT antigen sustains also serum-
independent growth of human fibroblasts (Shuda et al. 2011). In UISO MCC cell lines, 
ectopically expressed mutant LT antigen impairs repair of UV-induced DNA damage and 
reduces expression of XPC, a protein that functions in DNA damage recognition, and 
expression of p53 and p21, proteins that induce cell cycle arrest after DNA damage 
(Demetriou et al. 2012). 
 
3. Molecular biology of Merkel cell carcinoma 
 
Besides to MCPyV, relatively little is known about other factors that contribute to MCC 
molecular pathogenesis. Commonly occuring genomic aberrations found in comparative 
genomic hybridization analysis of MCCs are gains of 1q, 3q, 5p, 8q and within chromosome 
6, and losses of 3p, 13q and within chromosome 4 (Larramendy et al. 2004, Van Gele et al. 
2002, Popp et al. 2002, Paulson et al. 2009). In general, MCPyV-positive MCCs contain 
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fewer genetic aberrations than MCPyV-negative MCCs (Paulson et al. 2009). Amplification 
of the L-Myc proto-oncogene in 1p34 is found in 39% of MCCs (Paulson et al. 2009).  
Approximately 15% of MCCs contain p53 tumor suppressor protein mutations (Van Gele et 
al.  2000,  Lassacher  et  al.  2008),  and  expression  of  p63,  another  p53  family  protein,  is  
associated with unfavorable outcome (Asioli et al. 2011). PIK3CA mutations are also found in 
MCC, and the mutated tumor cells might thus be sensitive for PI3K/AKT-pathway inhibitors 
(Nardi  et  al.  2012,  Hafner  et  al.  2012).  Epigenetic  inactivation  of  tumor  suppressor  gene  
RASSF1A expression by hypermethylation of the promoter region is found in 51% of MCCs 
(Helmbold et al. 2009). 
 
Some studies have assessed expression of an anti-apoptotic protein Bcl-2 and found it to be 
expressed frequently in MCC (Plettenberg, Pammer & Tschachler 1996, Feinmesser et al. 
1999, Tucci et al. 2006, Sahi et al. 2012). However, in a multicenter phase II trial carried out 
in a series of 12 patients with advanced MCC and treated with a Bcl-2 targeting agent 
(G3139, Genasense), no responses were observed, suggesting that Bcl-2 may not have a key 
role in MCC tumorigenesis (Shah et al. 2009). A small-molecule survivin inhibitor, YM155, 
has been reported to have a cytostatic effect on MCC xenograph tumors in mice (Arora et al. 
2012).   
 
Immunohistochemical studies on cell adhesion and migration linked proteins showed that P-
cadherin expression is associated with prolonged recurrence-free survival and the presence 
of  MCPyV  DNA  in  tumor  (Vlahova  et  al.  2012).  In  the  normal  tissues,  Merkel  cells  are  
connected to the surrounding keratinocytes by E- and P-cadherins, whereas in MCC this 
linkage is switched to N-cadherin, which might facilitate tumor cell invasion and migration 
(Werling et al. 2011). Tetraspanins CD9 and CD151 are also associated with outcome of MCC 
patients (Woegerbauer et al.  2010). Tumor CD151 expression is associated with poor overall 
survival, in line with its known role as a tumor invasion promoting factor (Woegerbauer et 
al. 2010, Wang et al. 2011). On the other hand, tumor CD9 expression is associated with 
favorable disease-free and overall survival in agreement with its function as a tumor and cell 
invasion suppressive factor (Woegerbauer et al. 2010, Wang et al. 2011). 
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Expression of the KIT receptor tyrosine kinase has been studied by many investigators of 
MCC. The proportion of tumors considered KIT-positive has varied widely in different 
studies, ranging from 7% to 89%  (Su et al. 2002, Feinmesser et al. 2004, Swick et al. 2007, 
Brunner et al. 2008, Krasagakis et al. 2009, Andea et al. 2010, Kartha, Sundram 2008). The 
variation in the proportion of KIT-positive tumors reported might be explained by use of 
different antibodies and epitope retrieval methods in immunohistochemistry (Yang et al. 
2009). The interest to study KIT in MCC was fuelled by the effectiveness of small molecule 
tyrosine kinase inhibitors in other human tumor types such as gastrointestinal stromal 
tumor and some melanomas, where KIT mutations activate downstream survival signaling 
routes important for cancer pathogenesis (Carvajal et al. 2011, Joensuu et al. 2001, Joensuu 
et al. 2011, George et al. 2009). However, KIT mutations have not been found in MCC 
(Andea et al. 2010, Kartha, Sundram 2008). PDGFRA and PDGFA expression is frequent in 
MCCs (Kartha, Sundram 2008, Swick et al. 2008), and single nucleotide substitutions are 
present within the PDGFRA gene (Kartha, Sundram 2008, Swick et al. 2008), but these are 
likely single nucleotide polymorphisms that are found at a high frequency also in healthy 
human populations. One study suggested that KIT expression in MCC tends be associated 
with an unfavorable clinical outcome (Andea et al. 2010), but other studies have not 
confirmed this (Su et al. 2002, Feinmesser et al. 2004, Llombart et al. 2005). Growth of the 
KIT-positive MCC-1 cell line could be inhibited with small molecule KIT inhibitors imatinib 
and nilotinib, but in a clinical trial imatinib turned out to be ineffective in treatment of 
patients with advanced MCC (Samlowski et al. 2010). However, a single patient response to 
pazopanib (an inhibitor of KIT and several other kinases) has been reported (Davids et al. 
2009).  
 
4. Host defence and MCC 
 
Already in 1909 Paul Ehrlich proposed that the immune system can repress growth of 
cancers that occur spontaneously and that cancers would otherwise manifest at an 
overwhelming frequency (Manjili 2011). This idea was refined in the 1950s to a hypothesis of 
cancer immunosurveillance by Burnet, who suggested that small tumors may develop and 
express antigens that provoke immunological reaction and tumor regression without causing 
clinical symptoms (Burnet 1957), and by Thomas who suggested that the immune system is 
evolutional necessity to protect multicellular organisms from malignancy (Dunn et al. 2002, 
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Manjili 2011). The concept of cancer immunosurveillance is supported by the observation 
that people with an immune deficiency such as organ transplant recipients, and HIV or AIDS 
patients are more susceptible to cancer, especially to cancers with a known infectious cause 
(Grulich et al. 2007). On the other hand, many cancers may evolve at sites of infection, 
chronic irritation or inflammation (Coussens, Werb 2002).  At present, it is understood 
better that the immune system has a complex role in tumorigenesis, it can either limit or 
enhance tumor growth and progression depending on the type of immune cells that may be 
activated in tumor tissue. 
 
4.1 Tumor infiltrating immune cells 
4.1.1 Lymphocytes 
 
B and T lymphocytes are cells of the adaptive immune system, and their immune response 
against neoplastic or infected cells is awakened after recognition of a specific foreign antigen 
by  cell  type-specific  receptors.  A  high  number  of  tumor  infiltrating  lymphocytes  (TILs)  is  
associated with a favorable outcome in many types of human cancer, such as melanoma, 
small cell lung carcinoma and carcinomas of  the ovary, colorectum, esophagus and breast 
(Clemente et  al.  1996,  Erdag et  al.  2012,  Hwang et  al.  2012,  Pages  et  al.  2005,  Pages  et  al.  
2005, Zhang et al.  2003, Galon et al.  2006, Schumacher et al.  2001, Mahmoud et al.  2011, 
Eerola, Soini & Paakko 2000). In particular, the presence of cytotoxic CD8-positive T cells 
was associated with a favorable outcome in a meta-analysis that compared the prognostic 
significance of different types of tumor infiltrating T cells in several types of malignancies 
(Gooden et al. 2011). This is supported by a finding that T helper (CD4+) cell and CD8+ cell 
deficient mice were more prone to 3’-methylcholantrene-induced sarcoma than wild type 
mice (Koebel et al. 2007), and in a spontaneous melanoma mouse model CD8+ cells were 
able to prevent growth of disseminated cells, but soon after CD8+ cell depletion the mice 
rapidly developed metastases (Eyles et al. 2010).  
 
Immunoregulatory CD4-positive T helper cells and their subtype, CD25+/FoxP3+ T 
regulatory (Treg) cells are generally thought to suppress anti-tumoral effects of cytotoxic T 
cells (Terabe, Berzofsky 2004). Depletion of CD4+/CD25+ cells with anti-CD25 (anti-
interleukin-2 receptor alpha) antibody in mice caused regression of tumors in four of five 
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cancer types examined in syngenic mice (Onizuka et al. 1999), and depletion of CD25+ cells 
together with administration of an antibody against a CTLA-4 antigen, the CD8+ cell 
responses downregulating antigen, resulted in a synergistic effect on B16 melanoma 
regression in mice (Sutmuller et al. 2001). Of note, overall survival of patients with 
metastatic melanoma improved when treated with an anti-CTLA-4 antibody ipilimumab plus 
dacarbazine as compared to dacarbazine alone in a large clinical trial (Robert et al. 2011). A 
recent meta-analysis demonstrated that tumor infiltrating FoxP3+ cells are associated with 
favorable prognosis in colon carcinoma, whereas they were associated with poor survival in 
hepatocellular cancer, and inconsistently with prognosis of several other tumor types 
(Deleeuw et al. 2012). These results suggest that Treg cells may have a different role 
depending on the tumor type. 
 
The functional role of B cells as tumor infiltrating lymphocytes (TILs) has not been studied 
extensively. B cells function as antigen presenting cells and produce antibodies against 
tumor-associated antigens, such as overexpressed or mutated proteins (Reuschenbach, von 
Knebel Doeberitz & Wentzensen 2009). Studies comparing B cell deficient and wild type 
mice showed that B cells may inhibit Th cell-mediated activation of anti-tumorigenic CD8+ 
cells (Qin et al. 1998, Shah et al. 2005), whereas DeLillo and colleagues found that depletion 
of mature B cells in wild type mice using a CD20-antibody increased melanoma growth and 
impaired  CD4+  and  CD8+  cell  activation  (DiLillo,  Yanaba  &  Tedder  2010).  B  cell  tumor  
infiltration is associated with favorable disease-specific survival in soft tissue sarcomas 
treated surgically with wide resection margins (Sorbye et al. 2011), and was recently found to 
be associated with favorable disease-specific and disease-free survival in a large breast 
cancer cohort (n=1470) (Mahmoud et al. 2012). 
 
Natural killer (NK) cells are cytotoxic cells of the innate immune system that recognize and 
kill neoplastic cells without need of prior sensitization, and attract other immune cells into 
their vicinity by releasing interferon-gamma (IFN-?) (Schoenborn, Wilson 2007). Their 
pivotal role in spontaneous resistance against tumor growth and metastasis has been shown 
in NK cell deficient or NK reactivity suppressed mice (Talmadge et al. 1980, Gorelik et al. 
1982). In humans, low NK cell activity is associated with familial melanoma (Hersey et al. 
1979) and increased risk of cancer (Imai et al. 2000).  
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4.1.2 Macrophages 
 
Macrophages are phagocytic cells of the innate immune system that can identify and kill 
tumor cells, engulf and digest cell debris, and induce anti-tumoral responses of the immune 
system by expressing immunostimulatory cytokines and by presenting digested tumor 
antigens for Th cells on their cell membrane MHC class II molecules (Jadus et al. 1996, 
Bingle, Brown & Lewis 2002). Several studies have found that presence of a high number of 
tumor-associated macrophages correlates with poor prognosis of cancer patients (Bingle, 
Brown & Lewis 2002, Lewis, Pollard 2006). The dual role of macrophages in cancer may be 
explained by their heterogeneity. Depending on the microenvironmental stimuli at the target 
tissue, monocytes can differentiate towards one of the two extremes of the macrophage 
lineage continuum; either to M1 macrophages, which activate immune responses against 
malignant cells or to M2 macrophages, which down-regulate M1-mediated immune 
responses, express less antigen-presenting MHC II protein, and promote angiogenesis, 
tumor cell invasion and metastases (Mantovani et al. 2002, Lewis, Pollard 2006, Movahedi 
et al. 2010). Tumor-associated macrophages are considered to be mainly M2 macrophages. 
 
4.2 Merkel cell carcinoma and immune cells 
 
Spontaneous regressions of MCC occur in up to 1.5% of patients, usually after a tumor biopsy 
(Inoue et al. 2000, Burack, Altschuler 2003, Herrmann et al. 2004, Kubo et al. 2007, 
Richetta  et  al.  2008,  Vesely  et  al.  2008,  Turk et  al.  2009,  Ciudad et  al.  2010).  At  least  two 
likely immune function-related complete remissions have been reported, one in MCC of the 
scalp with multiple local and regional metastases after topical treatment with the immune 
system-stimulating agent dinitrochlorobenzene (Herrmann et al. 2004), and the other one in 
a patient with metastatic MCC with HIV after antiretroviral therapy (Burack, Altschuler 
2003). Spontaneously regressing MCCs have more TILs compared to non-regressing tumors, 
suggesting that the immune system may sometimes restrict tumor growth (Inoue et al. 
2000). 
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A high number of tumor infiltrating mast cells and lymphocyte infiltrates are associated with 
favorable  prognosis  in  MCC  (Llombart  et  al.  2005,  Beer,  Ng  &  Murray  2008,  Andea  et  al.  
2008). In a more detailed study, Paulson and colleagues first identified a cluster of immune 
response-related genes from a gene expression profile, and the cluster was associated with 
good prognosis in a series of MCC patients. CD8 cell-associated genes turned out to be 
overexpressed in this gene cluster, and immunohistochemical staining of intratumoral CD8 
cells  confirmed  that  a  high  number  of  cytotoxic  T  cells  in  tumor  was  an  independent  
prognostic factor for favorable MCC-specific survival in a multivariate analysis (Paulson et 
al. 2011).  
 
The humoral immune response to MCPyV might also affect the outcome in MCC. 
Interestingly, the blood IgG antibody levels against the MCPyV VP1 capsid protein were 
higher in general in MCC patients than individuals without MCC (Tolstov et al. 2009, 
Pastrana et al. 2009). In one study, high blood VP1 antibody levels were associated with a 
low risk for MCC recurrence (Touze et al. 2011). The blood levels of anti-T antigen antibodies 
correlate with the tumor burden in MCC patients (Paulson et al. 2010). 
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AIMS OF THE STUDY 
 
1. To investigate the frequency of MCPyV infection in MCC and its association with patient 
and tumor characteristics, and survival. 
 
2. To investigate the associations between presence of MCPyV DNA and LT antigen 
expression in MCC, PDGFR family protein and cell cycle regulatory protein expression, 
TP53, KIT and PDGFRA mutations, and their associations with patient and tumor 
characteristics, and survival. 
 
3. To evaluate the frequency and type of tumor infiltrating immune cells in MCC, and to 
investigate their associations with the presence of MCPyV DNA in MCC and 
clinicopathological factors including patient outcome. 
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MATERIALS AND METHODS 
 
1. Patients and tumors 
 
Patients diagnosed with MCC in Finland from January 1, 1979 to October 24, 2004 were 
identified from files of the Finnish Cancer Registry. A total of 207 individuals with a 
diagnosis of MCC could be identified. The first case of MCC was diagnosed in Finland in 
1983. The Finnish Cancer Registry was founded in 1952, and a systematic survey on the 
coverage  of  the  registry  performed  in  1985  to  1988  found  the  registry  to  cover  99%  of  all  
solid tumors and 92% of hematologic malignancies diagnosed in Finland. The coverage of 
the registry thus approaches 100% (Teppo, Pukkala & Lehtonen 1994, Korhonen et al. 2002).  
 
From the 207 patients, thirty-seven were excluded due to lack of tumor tissue for histological 
review, 13 because the MCC diagnosis was not confirmed at histopathological review, and 
eight since the site of the primary tumor was not known; in 16 cases clinical data were not 
available.  A flow chart considering patient exclusion criteria for studies I to IV is provided in 
Figure 3.  
 
MCC diagnosis was confirmed when tumor morphology was compatible with MCC on 
hematoxylin-eosin-stained slides and the tumor cells were CK20-positive in 
immunohistochemistry. Three cases in which the tumor did not express CK20 were included 
in the series, because these tumors did express both synaptophysin and chromatogranin A. 
To exclude metastatic small cell lung carcinomas, negative immunostaining for TTF-1 was 
also required. Tumor histology was classified either as small cell, trabecular cell or 
intermediate cell type, following the World Health Organization criteria (Kohler, Kerl 2006).  
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Figure 3. Consort diagram. * MCC was considered positive if qPCR result > 0 in studies 1 
and 4, whereas in studies 2 and 3, cut-off for positivity was MCPyV DNA to PTPRG ratio > 
0.1. 
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Tumors containing mixed histological MCC subtypes were classified as trabecular cell 
subtype if the trabecular cell morphology was present, whereas tumors with mixed small cell 
and intermediate cell types without trabecular cell morphology features were classified as 
intermediate cell subtype. The tumor diameter was measured from hematoxylin-eosin 
stained slides whenever feasible. When the size could not be estimated from tissue sections, 
the diameter provided in case records was accepted. 
 
Clinical data were extracted from the hospital case records and from the case records of the 
primary care centers. The date and cause of death was obtained from the files of the Finnish 
Cancer Registry and the Register Office of Helsinki.  
 
2. Tissue microarray (II-IV) 
 
A representative region of MCC was identified from hematoxylin-eosin slides, and 0.6 mm 
diameter tumor tissue biopsy cores were used for construction of a tissue microarray (TMA). 
Two parallel sample cores were taken for each TMA block whenever feasible, and two 
parallel TMA blocks were made.    
 
3. Immunohistochemistry (II-IV) 
 
For all immunohistochemical stainings, a 5 µm tissue section was cut either from a TMA or a 
MCC tissue block on a SuperFrost+ slide (Menzel-Gläser, Braunschweig, Germany). The 
tissue sections were deparaffinised in xylene and rehydrated through a decreasing alcohol 
gradient. Endogenous peroxidase activity was blocked by incubating the sections in 3% 
hydrogen peroxide for 30 minutes, except for CD4 immunostaining, where blocking was 
performed with 0.5% hydrogen peroxide in methanol for ten minutes. The antibodies, their 
dilutions, incubation times and temperatures, and the methods used for antigen retrieval are 
given in Table 3. Binding of the primary antibody was detected by using a PowerVision+ 
Poly-HRP Histostaining kit (Immunovision Technologies Co, Daly City, California), except 
for CD3 and CD68 stainings, where detection was carried out using a double-labeling 
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method (impress Anti-mouse and Anti-rabbit Ig Polymer detection kits, Vector Laboratories 
Inc, Burlingame, California). Tissue samples with known antigen expression were used as 
positive and negative controls. The immunostainings were scored either based on the 
staining intensity or the percentage of positive cells. 
 
Table 3. A list of antibodies, their manufacturers, dilutions, pre-treatment 
buffers and methods used. 
        Protein Antibody  
clone 
Dilution  Incubation time 
and temperatute 
Pre-treatment 
buffer? 
Manufacturer 
        
Cyclin D1  SP4 1:50 30 min at RT SC + Autoclave Thermo Fisher Scientific, 
Fremont, CA 
Cyclin E  HE-12  1:100 30 min at RT SC + Autoclave Thermo Fisher Scientific 
Ki-67  MM1  1:500 overnight at 4°C SC + Autoclave Novocastra Laboratories 
Ltd,  
     Newcastle Upon Tyne, UK 
MCPyV LTA CM2B4  1:100 1h at RT SC + wb Santa Cruz Biotechnology, 
Inc, Santa Cruz, CA 
MDM-2  MDM2  1:100 overnight at 4°C SC + Autoclave Novocastra Laboratories Ltd 
p16  JC8  1:600 overnight at 4°C SC + Autoclave Santa Cruz Biotechnology, 
Inc 
p21  DCS-60.2  1:30 1h at RT SC + Autoclave Thermo Fisher Scientific 
p27 DCS-72.F6  1:150 1h at RT SC + Autoclave Thermo Fisher Scientific 
p53  DO7  1:500 overnight at 4°C  SC + Autoclave Novocastra Laboratories Ltd 
RB  1F8  1:200 30 min at RT SC + Autoclave Thermo Fisher Scientific 
Phospho-RB Ser807/811  1:400 overnight at 4°C SC + Autoclave Cell Signalling Technology, 
Inc, Danvers, MA 
CD3  SP7  1:100 30 min at RT SC + Autoclave Thermo Fisher Scientific 
CD4  NCL-CD4-1F6  1:50 1h at RT EDTA + wb Novocastra Laboratories Ltd 
CD8  SP16  1:100 20 min at RT SC + Autoclave Thermo Fisher Scientific 
CD16  2H7  1:20 20 min at RT SC + Autoclave Thermo Fisher Scientific 
CD68  PG-M1  1:50 30 min at RT SC + Autoclave Thermo Fisher Scientific 
CD163  10D6  1:70 20 min at RT SC + Autoclave Thermo Fisher Scientific 
CLEVER-1   1:10 overnight at 4°C Proteinase K Self produced (Palani et al. 
2011) 
FoxP3  236A/E7  1:300 1h at RT SC + Autoclave Abcam, Cambridge, UK 
KIT A4502 1:300 overnight at 4°C SC + wb DakoCytomation, Glostrup, 
Denmark 
PDGFRA C-20 1:1000 overnight at 4°C SC + Autoclave Santa Cruz Biotechnology, 
Inc 
SCF #2273 1:200 overnight at 4°C SC + wb Cell Signalling Technology, 
Inc 
Phospho-KIT Tyr719/#3391 1:35 overnight at 4°C SC + wb Cell Signalling Technology, 
Inc 
? wb = water bath (at 98°C for 20 to 30 minutes); SC = sodiumcitrate (10 µmol/L, pH 6.0), 
EDTA = Ethylenediaminetetraacetic acid (1 mmol/L, pH 9.0).  
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4. Polymerase chain reaction (I, II, IV) 
 
Genomic DNA was extracted from the tissue samples after deparaffinization using a QIAamp 
DNA Mini kit (Qiagen GmbH, Hilden, Germany), and polymerase chain reaction (PCR) was 
performed using a FastStart Taq DNA Polymerase dNTPack kit (Roche Diagnostics GmbH, 
Mannheim, Germany) according to the manufacturers’ instructions. The PCR reaction 
contained 50 ng of DNA, 1x PCR buffer, 2 mmol/L of MgCl2, 200 µmol/L of dNTP mix, 1 U of 
FastStart  DNA  polymerase  and  0.3  µmol/L  of  forward  and  reverse  primers  for  a  20  µL  
reaction. The primer sequences are shown in Table 4. The PCR cycling conditions consisted 
of an initial denaturation step (95 ºC, four minutes) followed by 40 to 60 cycles of 
denaturation (95 ºC, 30 seconds), annealing (at 60 ºC in study I and II, and at 56 ºC in study 
IV, 30 seconds), and elongation (72ºC, 45 seconds). The final elongation was performed at 
72 ºC for seven minutes. The PCR products were analyzed by agarose gel electrophoresis and 
ethidium bromide staining, and sequenced. To prevent contamination DNA samples and 
PCR products were handled in different rooms. In addition, a reaction without template 
DNA was amplified in PCR, to detect any possible contaminations on PCR reagents.  
 
5. Quantitative PCR (I-IV) 
 
MCPyV DNA was detected and its copy numbers measured by real-time quantitative PCR 
(qPCR) with hydrolysis probes. DNA (50 ng) was amplified in 20 µL using a LightCycler 480 
probe master kit (Roche Diagnostics GmbH) and a reaction mix containing 1x PCR buffer, 
100 nmol/L of probe for the target gene, 200 nmol/L of each primer specific for the MCPyV 
LT3 antigen gene sequence or for a protein-tyrosine phosphatase receptor gamma (PTPRG) 
exon 19 sequence used as a reference. The primers and probes were designed using the 
ProbeFinder program (www.universalprobelibrary.com, Roche Diagnostics GmbH), and the 
locked nucleic acid (LNA) probes (LNA probe 65 for PTPRG and LNA probe 6 for LT3) were 
obtained from the Universal ProbeLibrary Set (Roche Diagnostics GmbH). Primer sequences 
are given in Table 4. LT3 products were sequenced to verify specificity of qPCR. 
 
Table 4. Genes and exons analyzed, primer sequences and the 
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PCR annealing temperatures. 
 
Gene and Exon Primer sequence (5’->3’) 
  Forward Reverse 
 Study I   
 LT1* tacaagcactccaccaaagc tccaattacagctggcctct 
LT3* ttgtctcgccagcattgtag atataggggcctcgtcaacc 
VP1* tttgccagcttacagtgtgg tggatctaggccctgattttt 
PTPRG intron 2 tatgggagtgtgggatggtt taagctgggaggatcgctta 
      qPCR 
 
 
 LT 3 gcatctgcaccttttctagactc ttttgccttatagacttttccatatct 
PTPRG exon 19 ctacattgccacccaagga tccagttgttttgttcccaaat 
   
 Study II   
 TP53 exon 4.1 cctggtcctctgactgctct ggtgtaggagctgctggtg 
TP53 exon 4.2 gtccagatgaagctcccaga gccaggcattgaagtctcat 
TP53 exon 5 tctgtctccttcctcttcctaca aaccagccctgtcgtctct 
TP53 exon 6 caggcctctgattcctcact cttaacccctcctcccagag 
TP53 exon 7 cttgggcctgtgttatctcc gggtcagaggcaagcaga 
TP53 exon 8 gcttcttgtcctgcttgctt gggagtagatggagcctggt 
TP53 exon 9 ggagaccaagggtgcagtta ccccaattgcaggtaaaca 
   
 Study IV   
 KIT exon 9 gtatgccacatcccaagtgt catgactgatatggtagaca 
KIT exon 11 ccagagtgctctaatgactg ggaagccactggagttcctt 
KIT exon 13 gacatcagtttgccagttgt tgttttgataacctgacagac 
KIT exon 17 gcaacactatagttattaaaaag cctttgcaggactgtcaagca 
PDGFRA exon 10 cccaactccttgccatctta tcagctgatgagttgtcctga 
PDGFRA exon 12 atgtggagtgaacgttgttgg ctagttcttactaagcacaagc 
PDGFRA exon 14 gctcagctggactgatatgtga ccagtgaaaatcctcactcca 
PDGFRA exon 18 caggggtgatgatgctattcagc ttaaagtgaaggaaggatgagcc 
 
* Primer sequences provided in Feng et al. (Feng et al, 2008) 
 
The PCR cycling consisted of an initial denaturation step (at 95 ºC, for ten minutes), 
followed by 45 cycles with denaturation (95 ºC, ten seconds), annealing (60 ºC, 30 seconds) 
and elongation (72 ºC, 45 seconds) steps. The fluorescence at the end of the annealing step of 
each cycle was measured, and the collected data were analyzed using the Advanced Relative 
Quantification software (Roche Diagnostics GmbH). The MCPyV DNA content of each tissue 
sample was expressed in relation to that of MCPyV DNA to PTPRG DNA. A calibrator sample 
was chosen from a randomly selected set of 88 MCC samples analyzed in a preliminary qPCR 
run based on a criterion that the sample had a crossing point (Cp) value near the median Cp 
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value of the series. The calibrator sample was subsequently used also for construction of the 
standard curve for the target and reference genes. 
 
6. DNA sequencing and sequence analyses (I, II, IV) 
 
PCR products were subjected to treatment with an ExoSAP IT enzyme mix (USB 
Corboration, Cleveland, Ohio) prior to sequencing. Sequencing of the template was 
performed in both directions using BigDye3 termination chemistry and an ABI 3100 Genetic 
Analyzer (Applied Biosystems, Foster City, California). The acquired sequences were 
compared with the reference sequences of MCPyV isolates MCC350 (gb/EU375803.1) and 
MCC339 (gb/EU375804.1) obtained from the Entrez Nucleotide database of National Center 
for Biotechnology Information, and with a human gene sequence database obtained from the 
Ensembl database. The sequences were analyzed by using a LaserGene 7.2 softaware 
(DNASTAR, Inc, Madison, Wisconsin). 
 
7. Statistical analysis (I-IV) 
 
Frequency tables were analyzed using the chi2 test or Fisher’s exact test. Continuous 
distributions between categorical groups were compared using the Mann-Whitney U test or 
the Kruskal-Wallis test. Correlation of continuous variables was analyzed using the 
Spearman’s rank correlation test.  
 
Cumulative survival was analyzed with the Kaplan-Meyer method, and survival between 
groups was compared using the log-rank test or Breslow’s test. The independence of 
variables for survival was assessed using Cox’s proportional hazard model. Overall survival 
was measured from the time of diagnosis to death from any cause, censoring patients alive 
on the last date of follow-up. MCC-specific survival was computed from the date of diagnosis 
to death caused by MCC, censoring patients alive at the time of data collection and those who 
died from another cause. Locoregional recurrence-free survival was analyzed from the date 
of diagnosis to the date of locoregional recurrence, censoring patients who did not have 
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locoregional recurrence on the date of last follow-up and those who died without 
locoregional recurrence on the date of death. Proportional hazard assumptions for covariates 
were evaluated using log-minus-log plots before covariate entry into the Cox’s proportional 
hazard model. All P-values are 2-sided and not adjusted for multiple testing. 
 
8. Ethical aspects (I-IV) 
 
The tumor tissue samples were originally collected for diagnostic purposes, and leftover 
tissue was collected from the archives of pathological departments. The Institutional Review 
Board of the Helsinki University Helsinki Central Hospital approved the studies, and the 
Ministry of Social Affairs and Health granted a permission to collect clinical data and the 
National Authority for Medicolegal Affairs a permission to collect tissue samples for the 
studies.  
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RESULTS 
 
The findings of the thesis are summarized here. More details can be found in the four articles 
that follow the reference list.  
 
1. Presence of MCPyV DNA, MCPyV LT antigen expression, clinical factors and 
disease outcome (I and II) 
 
MCPyV  DNA  was  detected  using  qPCR  in  91  (79.8%)  of  the  114  MCC  tumors  studied.  The  
MCPyV LT antigen was expressed in 61 (67.0%) of the 91 tumors analyzed by 
immunohistochemistry. The presence of MCPyV DNA and LT antigen expression were 
strongly associated (p<0.0001), although 12 (40.0%) of the 30 LT antigen-negative MCCs 
contained viral DNA. Five (41.7%) out of these 12 LT antigen-negative tumors contained 
MCPyV  DNA  in  low  levels  (MCPyV  DNA  to  PTPRG ratio less than 0.02), suggesting that 
MCPyV might be a passenger virus in these cases and that such tumors may not present true 
MCPyV-associated  MCC.  We  found  little  of  MCPyV  DNA  also  in  samples  of  skin  tumors  
other than MCC, and the viral LT antigen was not expressed in these tissues (unpublished 
data). The quantitative PCR was more sensitive in detection of MCPyV DNA than the 
qualitative PCR with amplicon detection by agarose gel electrophoresis and ethidium 
bromide staining. Due to the close association between the qPCR results and viral LT antigen 
immunostaining, the latter appears to be a useful marker for the presence of MCPyV 
infection in tumor. 
 
Neither presence of MCPyV DNA nor the LT antigen expression were associated with patient 
age at the time of diagnosis (p>0.05), while both factors were associated with MCC location 
in the limbs compared to the head and neck region or the trunk (both p-values ?0.015). 
Tumor LT antigen expression was significantly associated with the female gender (p=0.021) 
and with tumor intermediate morphology as compared to the trabecular or small cell types 
(p=0.023), but these comparisons were not significant when the presence of MCPyV DNA in 
tumor was examined in place of tumor LT expression (p=0.109 and 0.327, respectively). 
Tumors that harbored MCPyV DNA gave less often rise to regional nodal metastases at the 
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time of diagnosis than MCPyV-negative MCCs (6.6% vs. 21.7%, respectively; p=0.043), and 
in line with this, MCCs that expressed LT were less often stage III or stage IV than tumors 
lacking LT expression (6.5% vs. 30.0%, respectively; p=0.006). 
 
Presence of MCPyV DNA in tumor was associated with favorable disease-specific and overall 
survival rates compared to MCPyV DNA-negative cases (hazard ratio [HR] 0.37; 95% 
confidence interval [CI], 0.15 to 0.89; p=0.022; and HR 0.39; 95% CI, 0.24 to 0.65; p<0.001, 
respectively). Similarly, tumor LT antigen expression was associated with favorable MCC-
specific survival (HR 0.22; 95% CI, 0.09 to 0.52; p=0.0005) and overall survival (HR, 0.40; 
95% CI, 0.24 to 0.65; p=0.0002) compared to LT-negative cases. Presence of MCPyV DNA 
was an independent prognostic factor for favorable overall survival in a Cox multivariable 
analysis exluding patients with distant metastases (n=4), and with gender and presence of 
regional lymph node metastases at the time of the diagnosis entered as covariables in 
analysis (HR 0.42; 95% CI, 0.25 to 0.71; p=0.001). Similarly, tumor LT antigen expression 
was associated with favorable overall survival when entered as a covariable in a Cox 
multivariate analysis together with tumor stage (HR, 0.49; 95% CI, 0.29 to 0.83; p=0.008). 
 
2. Cell cycle regulatory proteins and MCPyV in MCC (II) 
 
Retinoblastoma protein (RB) expression was strongly associated with tumor LT antigen 
expression in MCC. All LT antigen expressing tumors co-expressed also RB (n=61) and only 
four  (13.3%)  of  the  30  LT  antigen  negative  tumors  expressed  RB  (p<0.0001).  The  MCPyV  
DNA to PTPRG ratio was higher in RB-positive than RB-negative tumors (median, 2.03; 
range, 0 to 4224 vs. median, 0; range 0 to 1149, respectively; p<0.0001). Among the 90 cases 
in which data on tumor LT expression, RB expression and MCPyV DNA status were 
available, only 11 (12.1%) tumors showed discordance between any of the three factors. As 
presence of MCPyV DNA and LT expression, as well as tumor RB expression were associated 
with favorable MCC-specific and overall survival (HR, 0.63; 95% CI, 0.47 to 0.84; p=0.0016; 
and  HR  0.36;  95%  CI,  0.21  to  0.60;  p<0.0001,  respectively).  Phosphorylated  RB  was  
expressed  in  54  (61.4%)  out  of  the  88  tumors  available  for  this  analysis,  but  tumor  RB  
phosphorylation status was not associated with the presence of MCPyV DNA in tumor or 
with the tumor LT antigen status. 
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The MCCs examined were highly proliferating tumors, and 97.8% of them expressed the Ki-
67 protein. The median percentage of Ki-67-positive tumor cells was lower in LT antigen 
expressing tumors than in the LT antigen-negative ones (52.3% vs. 61.4%, p=0.004). The cell 
cycle promoting protein, cyclin D1, was absent in almost all tumors (97.6%), whereas cyclin 
E was expressed in 78 (94.0%) of the 83 tumors investigated. Cyclin E expression was more 
often seen in LT antigen-positive than in -negative tumors (98.2% vs. 85.2%, p=0.037). The 
cell  cycle  inhibitor  protein  p16  was  expressed  in  97.7%  of  the  tumors,  and  p21  and  p27  in  
50.6% and in 70.0% of them, respectively. Expression of none of these cyclin-dependent 
kinase inhibitors was significantly associated with tumor MCPyV LT antigen expression, 
although expression of p27 tended to be higher in MCPyV LT-positive tumors (p=0.051). 
 
3. Tumor suppressor gene TP53 mutations and p53 expression in MCC (II, IV) 
 
Expression of p53 was investigated in Studies II and IV. It was found to be uncommon in 
MCPyV DNA-positive (15.3%) and LT antigen-positive (7.0%) tumors, whereas MCPyV 
DNA-negative and LT antigen-negative tumors frequently expressed p53 (45.0% and 43.3%; 
p=0.01 and p<0.0001, respectively). p53 expressing tumors contained also lower MCPyV 
DNA copy numbers compared to p53-negative tumors. The murine double minute 2 protein, 
a negative regulator of p53, was rarely expressed in MCCs (5.8%).  
 
TP53 mutations were highly significantly associated with tumor p53 expression (p=0.002), 
and eight (61.5%) of 13 p53-expressing tumors contained a TP53 mutation in gene exons 5 to 
9, which were sequenced in 39 MCCs. Only three (11.5%) of 26 p53 expression-negative 
tumors harbored TP53 mutation. In two of these cases the mutation caused a premature stop 
codon in the TP53 reading frame and in one case p53 expression was cytoplasmic instead of 
nuclear, wherby this tumor was considered p53-negative. TP53 mutations were found 
exclusively among the LT antigen-negative MCCs. The TP53 mutations are listed in Table 5. 
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Table 5. TP53 mutations found in Merkel cell carcinoma, and tumor p53, RB 
and LT antigen expression  
Case                          
TP53 
mutation 
type
Mutated 
exon 
p53 
expression 
RB 
expression 
LT antigen 
expression 
MCPyV 
status 
(copy no.) 
1. 
Substitution 
(c.298C>T; Q100X)    4  -              - - -  
2.       
Substitution 
(c.488A>G; Y163C)    5 +             - - -  
3.       
Substitution 
(c.517G>A; V173M)  5  N.A.            N.A.    - -  
4.       
Substitution 
(c.535C>A; H178N)  5 +               - - + (0.066)  
5.      
Substitution 
(c.536A>G; H178R)   5 +               - - + (0.014) 
6.       
Substitution 
(c.580C>T; L194F)   6 +               - - + (0.286)   
7.       
Substitution 
(c.586C>T; R196X)    6 -                - - - 
8.       
Substitution 
(c.844C>T; R282W)   8 +             - - -  
          
Substitution 
(c.856G>A; E286K)  8 
    
9.       
Substitution 
(c.845G>C; R282P)    8 +                - - - 
10.     
Deletion       
(c.938_966del)          9 -     - - -  
11.     
Deletion       
(c.940_941del)           9 +              - - -  
12.     
Deletion       
(c.951_954de)           9 +                - - - 
 
Patients whose tumor expressed p53 had poorer MCC-specific survival than those with p53-
negative cancer (5-year survival 44.0% vs. 76.4%, respectively; p=0.021), and they also had 
poorer overall survival (5-year survival 22.2% vs. 39.3%, respectively; p=0.046). When the 
tumors were stratified according to the presence of MCPyV DNA and p53 expression, those 
patients whose tumor contained MCPyV DNA but did not express p53 had the best outcome 
as compared to the other groups.  
 
4. KIT and platelet-derived growth factor receptor alpha in MCC (IV) 
 
A  total  of  59  (67.8%)  out  of  the  87  MCCs  investigated  showed  KIT  protein  expression  of  
some degree in immunohistochemistry. The expression was classified as negative, faint, 
moderate  or  strong  in  28  (32.2%),  22  (25.3%),  23  (26.4%)  and  14  (16.1%)  of  the  tumors,  
respectively. The MCCs with moderate or strong expression were considered KIT-positive in 
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further analyses. KIT expression was found more frequently in MCPyV DNA-negative than in 
DNA-positive tumors (34.3% vs. 70.0%, p=0.009). Phosphorylated KIT was detected only in 
four (4.8%) of the 83 MCCs studied, suggesting that KIT is rarely activated in MCC. The KIT 
ligand (SCF) expression was also rarely found (seven [8.6%] of 81), suggesting that ligand-
dependent activation of KIT occurs infrequently in MCC. PDGFRA expression was detected 
in 23 (31.9%) out of the 72 tumors investigated. 
 
KIT exons  9,  11,  13  and  17,  and  the  corresponding  PDGFRA exons  10,  12,  14  and  18,  were  
investigated by DNA sequencing in 50 MCCs. All eight exons were successfully sequenced in 
34 cases, seven exons in 11 cases, and six exons in five cases. No activating mutations in KIT 
or PDGFRA were found. Eight tumors contained a 1432T>C single nucleotide substitution in 
PDGFRA exon 10. Thirty additional MCCs were investigated for this PDGFRA exon 10 
alteration and a total of ten (12.5%) of the 80 tumors contained the same S478P single 
nucleotide polymorphism. The S478P alteration was not associated with PDGFRA 
expression or with the presence of MCPyV DNA, but it was found more commonly in KIT-
positive than KIT-negative tumors (23.5% vs. 4.3%, p=0.015). 
 
Patients whose tumor expressed KIT tended to have less favorable overall survival compared 
to patients with KIT-negative MCC (5-year survival 42.0% vs. 27.0%; p=0.050 by the 
Breslow test). When the MCCs were stratified based on the presence of MCPyV DNA and KIT 
expression, those patients whose tumor was KIT-positive and MCPyV DNA-negative had the 
worst overall survival and tended to have also the worst disease-specific survival. 
 
5. Tumor infiltrating immune cells in MCC (III) 
 
The numbers of tumor infiltrating T lymphocytes (CD3+) and their subsets, cytotoxic T 
lymphocytes (CD8+), helper T cells (CD4+) and regulatory T cells (FoxP3+), and natural 
killer cells (CD16+) and macrophages (CD68+) including M2 macrophages (Clever-1+ and 
CD163+) were investigated in 116 MCCs using immunohistochemistry. The median numbers 
of tumor infiltrating CD3+, CD8+, CD16+ , FoxP3+ and CD68+ cells were higher in MCPyV 
DNA-positive MCCs than in MCPyV DNA-negative cancers (all p-values <0.05). Similarly, 
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the  median  numbers  of  CD3+,  CD4+,  CD8+,  FoxP3+  and  CD68+  cells  were  higher  in  LT  
antigen-positive than LT antigen-negative MCCs (all p-values <0.05). Intratumoral Clever-1-
positive cells were rarely found, although they were frequently present in the stroma 
surrounding the tumors. 
 
MCCs with a high number of intratumoral CD3+ lymphocytes were infrequently p53-positive 
(p<0.001) or presented with regional or distant metastases at the time of diagnosis 
(p=0.006)  compared to  MCCs with a  low number of  CD3+ cells,  but  they were more often 
RB-positive (p=0.012) and p27-positive (p=0.030). MCCs with a high tumor CD8+ or 
FoxP3+ cell count expressed less often p53 than MCCs with a low count, and the RB protein 
was often expressed when the tumor CD4+ or FoxP3+ cell count was high (all p-values 
<0.05). A high number of intratumoral CD8+, FoxP3+ and CD163+ cells was associated with 
a larger than the median tumor diameter (16 mm) at the time of the diagnosis (all p-values 
<0.05). None of the tumor infiltrating immune cell types investigated was associated with 
gender, age at the time of diagnosis or tumor proliferation rate as assessed with Ki-67 
immunostaining. 
 
High number of CD3+ lymphocytes in tumor associated with favorable MCC-specific and 
overall survival (both p-values ? 0.002). Similarly, a high number of CD8+ and FoxP3 cells 
was significantly associated with favorable survival, whereas the CD4+ counts were not. 
Interestingly, a low CD8+/CD4+ ratio (<0.38) and a low FoxP3+/CD4+ cell ratio (<0.25) 
were associated with poor survival (p=0.007 and p=0.002, respectively), whereas the 
CD8+/FoxP3+ ratio was not significantly associated with survival (p=0.743). A number of 
natural killer cells or macrophages were not associated with overall survival (Table 6). 
 
A higher than median tumor CD3+ cell count was significantly associated with favorable 
overall survival in the subset of MCPyV DNA-negative MCC (HR, 0.33; 95% CI, 0.13 to 0.85; 
p=0.022) and tended to be associated with favorable survival also in MCPyV DNA-positive 
cancer (HR, 0.64; 95% CI, 0.39 to 1.05; p=0.074). A high tumor CD8+ count was associated 
with  favorable  survival  in  MCPyV  DNA-positive  MCC  (HR,  0.46;  95%  CI,  0.23  to  0.92;  
p=0.028). When the MCCs were stratified into four subgroups based on the presence or 
absence of  MCPyV DNA and the tumor CD3+ or  CD8+ cell  counts  (high vs.  low),  patients  
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with MCPyV DNA-positive tumor and with a high CD3+ or CD8+ count had the best 
outcomes, whereas patients with a low CD3+ count and MCPyV DNA-negative tumor had 
the worst survival. In Cox multivariable proportional hazard model, lower than median 
tumor CD3+ cell count was an independent adverse prognostic factor for overall survival 
when entered in analysis as a covariable together with gender, the regional nodal status 
(patients with distant metastases at the time of the diagnosis were excluded from the 
analysis) and the tumor MCPyV DNA status (Table 7).  
 
Table 6. Univariate Cox proportional hazard analysis for overall survival 
Covariate† Hazard ratio of death 
95% 
confidence 
interval p-value 
CD3 0.51 0.34 to 0.78 0.002 
CD4 0.94 0.70 to 1.26 0.937 
CD8± 0.45 0.26 to 0.77 0.004 
CD16 0.72 0.46 to 1.14 0.163 
FoxP3 0.57 0.36 to 0.91 0.019 
CD68 0.88 0.58 to 1.32 0.529 
CD163 1.22 0.80 to 1.86 0.357 
CD8/CD4 ratio? 2.07 1.22 to 3.51 0.007 
FoxP3/CD4 ratio? 2.29 1.35 to 3.88 0.002 
†Patients with higher than median cell count were compared to rest of the patients.            
±The quartiles of second to fourth vs. the lowest were compared.                                              
?The lowest quartile vs. the rest were compared. 
 
Table 7. Multivariable Cox proportional hazard analysis of overall survival 
Covariate 
Hazard ratio 
of death 
95% 
confidence 
interval p-value 
CD3+ count 
     (median ?vs. >) 1.91 1.21 to 3.01 0.005 
Nodal metastases 
     Presence vs. absence 2.96 1.46 to 6.01 0.003 
Sex 
     Male vs. female 1.78 1.10 to 2.87 0.018 
MCPyV DNA 
     Absent vs. present 1.93 1.20 to 3.10 0.007 
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DISCUSSION 
 
In the present thesis, we investigated the associations between several clinical and molecular 
factors and MCPyV infection in a large Finnish population-based MCC series. We showed 
that MCC patients with MCPyV-positive cancers generally have better outcome in 
comparison to patients with MCPyV-negative tumor. The reasons for this are not yet known, 
but we found that the MCPyV-positive and -negative tumors differ in several aspects at the 
molecular level. For example, MCPyV-positive tumors express frequently RB, whereas in 
MCPyV-negative cancers RB expression is usually absent, whereas p53- and KIT-expression 
is more common, and TP53 mutations may be found exclusively in MCPyV-negative tumors. 
Tumor microenvironment also differs in MCPyV-positive and -negative MCCs with higher 
numbers of tumor infiltrating leukocytes being present in virus-positive tumors. 
 
1. MCPyV-positive and -negative tumors as two distinct molecular subtypes 
 
At present, the prognostic significance of tumor MCPyV status is controversial in MCC. 
Although some studies have found an association between favorable disease outcome and 
MCPyV-positivity  (Laude  et  al.  2010,  Bhatia  et  al.  2010a,  Andres  et  al.  2009,  Nardi  et  al.  
2012), other studies have not found such an association (Schrama et al. 2011, Asioli et al. 
2011, Handschel et al. 2010). The different results may in part be explained by the sensitivity 
of the methodology used to detect MCPyV DNA. Three out of seven studies cited above used 
qPCR for viral DNA detection, and found MCPyV in 74% to 94% of the cases (Schrama et al. 
2011,  Laude  et  al.  2010,  Bhatia  et  al.  2010b),  while  three  other  studies  used  PCRs  with  
relative short amplicons (109bp to 195bp), and detected MCPyV DNA in only 66% to 76% of 
the cases (Andres et al. 2009, Nardi et al. 2012, Asioli et al. 2011). Handschel and colleagues 
found the lowest percentage of MCPyV DNA-positivity in the tumors examined (58%) 
(Handschel et al. 2010), probably because they used a PCR employing primer pairs for LT1, 
LT3 and VP1 coding regions, which we had found less sensitive than the qPCR used here 
(49.5% vs. 79.8% of the tumors were found MCPyV-positive). 
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Differences in the comprehensiveness of the patient series studied might also explain the 
differences in results on the association between MCPyV infection and patient outcome. At 
present, our series is the only population-based one probably involving the least selection 
bias. The numerically largest series (n=174) was obtained from Europe and Australia 
(Schrama et al. 2011). Furthermore, the tumor materials in some studies included both 
formalin-fixed paraffin-embedded samples and frozen tissue samples, as well as samples 
from the primary tumors, recurrent tumors and metastatic tissues adding further 
heterogeneity. These factors probably reflect the difficulties in obtaining adequate numbers 
of tissue samples from a rare tumor type.  
 
Schrama and colleagues suggested that the favorable outcome of MCPyV DNA-positive MCC 
patients in the present series might be explained by an exceptional gender distribution with a 
female predominance (Schrama et al. 2011). Such gender distributions in MCC series are 
typical  for  the  Nordic  countries  (Kaae  et  al.  2010,  Kukko  et  al.  2012),  but  a  female  
predominance was also present in three out of the seven studies referred to above (Laude et 
al. 2010, Andres et al. 2009, Handschel et al. 2010). Of note, men were predominant in the 
series of Bhatia et al. and Nardi et al. in which MCPyV-positivity was associated with 
favorable outcome, indicating that the gender distribution does not explain the effect of 
MCPyV infection on survival (Bhatia et al. 2010a, Nardi et al. 2012).  
 
Another striking difference between the series is that regional lymph node and distant 
metastases were found at the time of diagnosis less frequently in our series and those of 
Laude et al. and Andres et al. (14%, 25% and 17%, respectively), whereas in the series of 
Asioli et al. and Schrama et al. metastases were found more often (43% and 39%, 
respectively). The reasons why the MCCs appear to be more advanced at the time of the 
diagnosis in some series remain speculative, but this may impact the results. The patient- 
and doctor-related delays might vary between countries leading to some tumors being 
diagnosed at a more advanced stage at the time of the diagnosis (Blendon et al. 2002). A 
large proportion of metastatic MCCs in the series of Nardi et al. (53%) may be explained the 
fact that the patients originated from an institute where more advanced cases of MCCs are 
being treated (Nardi et al. 2012). However, we found in a Cox multivariable analysis that 
absence of MCPyV DNA in tumor was an independent adverse prognostic factor besides the 
male gender and the nodal status.  
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In addition to the association with patient outcome, the tumor viral status correlates with 
some clinical factors, suggesting that MCPyV-positive and -negative tumors might be two 
distinct molecular subtypes of MCC. As compared with MCPyV LT antigen-negative tumors, 
LT-positive tumors are more common in females than males (75% vs. 50%), and they are 
located more often in the limbs than in the trunk (54% vs. 8%). This observation has been 
confirmed by two independent studies on relatively large MCC series (n=174 and n=60; 
Schrama et al. 2011, Nardi et al. 2012). It is possible that MCPyV-driven tumorigenesis takes 
place more often in sun exposed skin areas, since UV radiation activates MCPyV sT antigen 
expression (Mogha et al. 2010) that is required for cell transformation and promotes cell 
proliferation (Shuda et al. 2011). The differences in MCC gender distribution might result 
from yet unknown sex-related biological or hormonal mechanisms that may affect Merkel 
cells. 
 
In addition to the clinical observations discussed above, several molecular findings support 
the hypothesis that MCCs could be divided into two distinct molecular subtypes based on the 
MCPyV status. We found that tumor RB expression is almost invariably associated with 
MCPyV-positivity and that TP53 mutations were exclusively found in LT antigen-negative 
MCC. In line with this, Bhatia and his colleagues reported RB and terminal 
deoxyribonucleotidyl transferase expression to be more frequent in MCPyV-positive tumors, 
whereas p53 expression was less common (Bhatia et al. 2010b). In another study that 
addressed the correlation between TP53 mutations and the MCC MCPyV status, the authors 
reported TP53 mutations  in  only  3  (5%)  of  60  MCCs  studied  (Nardi  et  al.  2012),  a  
substantially lower figure than ours (28%). The lower number of mutations detected may 
reflect the differences between the series or technical factors such as the genotyping assay 
used (Dias-Santagata et al. 2010). Interestingly, two of the mutations were found in MCPyV 
DNA-positive tumor samples (Nardi et al. 2012). Three of the eleven MCCs that contained a 
TP53 mutation in the present series harbored a low copy number of MCPyV DNA, and LT 
antigen expression was absent, suggesting that these tumors may not have been MCPyV 
infection-associated (Table 5).  
 
We found changes also in the expression of other cell cycle-related proteins. Cyclin E 
expression was more common in MCPyV-positive than in MCPyV-negative MCCs, whereas 
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the cell proliferation rate assessed by Ki-67 staining was higher in MCPyV-negative cancers. 
Studies performed in MCC cell lines support these findings. RB sequestration by MCPyV LT 
antigen activates expression of the G1 to S phase transition promoting proteins cyclin E and 
E2F1 in a BJ fibroblast cell line, whereas mutant, RB-binding inefficient LT antigen does not 
(Arora et al. 2012). In one study, MCPyV-negative cell lines had shorter doubling times than 
MCPyV-positive ones (Houben et al. 2010), which is in line with the higher cell proliferation 
rate found in the present series in MCPyV-negative MCCs. In addition, KIT expression was 
more common in MCPyV-positive than MCPyV-negative tumors, although KIT was rarely 
activated in the current series and, therefore, might not be a suitable target for therapeutic 
agents such as pazopanib, a multitarget tyrosine kinase inhibitor with which a response was 
achieved in a single MCC patient in one study (Davids et al. 2009). Further differences 
between MCPyV-positive and MCPyV-negative MCCs have been reported. MCPyV-negative 
MCCs contain more genomic aberrations than MCPyV-positive counterparts (Paulson et al. 
2009), and most PIK3CA mutations are found in MCPyV-negative cancer (Nardi et al. 2012). 
 
It has been also suggested that instead of two etiologically different oncogenic pathways 
leading to MCPyV-positive and –negative MCC, MCPyV-negative cancers might have lost the 
virus (Houben et al. 2012b). Houben et al. have studied MCPyV-positive cell line (LoKe), 
which genome contains integrated virus genome. LT antigen is expressed in LoKe cells and 
MCPyV-genome contains LT antigen truncating mutation characteristic for cancer, although 
including also exceptional deletion in RB bindind region (Houben et al. 2012b). T antigen 
silencing with shRNA didn’t inhibited cell growth as with other MCPyV-positive cell lines 
(Houben et al. 2012a, Houben et al. 2012b). Authors suggested that in some cases MCPyV is 
effective in tumor initiation, and after additional mutations accumulate in cell, T antigen 
becomes dispensable; therefore, MCPyV-genome might be lost from cells (Houben et al. 
2012b). We can’t rule out that MCPyV-genome is lost in our samples, although several 
different aberrations are found in MCPyV-positive and –negative MCCs suggesting different 
different oncogenic pathways in these tumors. 
 
Interestingly, MCC shows features similar to those of another virus infection-related cancer, 
oropharyngeal squamous cell carcinoma. Up to 72% of oropharyngeal head and neck cancers 
in the United States and Europe are infected with the human papillomavirus (HPV) 
(Mehanna et al. 2012). The majority of HPV-positive head and neck cancers harbor the high-
risk HPV-16 strain (D'Souza et al.  2007). In analogy with the polyomavirus T antigens, the 
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double-stranded DNA genome of HPV encodes E6 and E7 proteins, which target the p53 and 
RB tumor suppressor proteins; and suppression of E6 and E7 proteins by shRNA induced 
cancer cell apoptosis in a oropharyngeal squamous carcinoma cell line (Rampias et al. 2009). 
In line with our results in MCPyV-positive MCCs, patients with HPV-positive head and neck 
cancers show better disease outcome than those with HPV-negative cancers (Arora et al. 
2012, Ang et al. 2010, Gillison et al. 2000), and HPV-positive head and neck cancers harbor 
TP53 mutations infrequently (Gillison et al. 2000, Kumar et al. 2008, Perrone et al. 2006). 
These features in common with HPV-positive head and neck cancers and MCPyV-positive 
MCCs suggest that the two virus families function alike in tumorigenesis and that the viral 
status of the tumor associates with distinct molecular subtypes with different oncogenic 
pathways. 
 
2. Immune cell infiltration and outcome in MCPyV-positive and MCPyV-
negative MCCs 
 
The observation that MCPyV-positive MCCs contain a higher number of tumor infiltrating 
immune cells than virus-negative tumors might explain in part the generally more favorable 
outcome of patients with MCPyV-positive cancers along with the molecular differences 
discussed above. Interestingly, a high number of tumor infiltrating T lymphocytes is 
associated with favorable survival in both MCPyV-positive and MCPyV-negative MCC. 
However, those patients whose tumor was MCPyV-positive and contained a high number of 
CD3+ or CD8+ cells had the best overall survival, indicating that intratumoral T cell 
infiltration is beneficial for survival regardless of the tumor MCPyV status, although MCPyV-
positivity also had independent influence on survival as a single factor. Thus far one other 
study has found a high intratumoral CD8 count to be associated with a favorable outcome in 
MCC (Paulson et al. 2011). MCC is associated with immunocompromised conditions such as 
HIV/AIDS, chronic lymphocytic leukemia, immunosuppressive therapies, UV-exposure 
(Agelli,  Clegg  2003,  Heath  et  al.  2008)  and  old  age  (Vukmanovic-Stejic  et  al.  2011).  
Therefore, it may not be surprising that immune cells have tumor growth restricting function 
in MCC, in a virus-associated skin tumor that appears in elderly person. Similarly, the longer 
known polyomaviruses BKPyV and CJPyV persisting latently can be reactivated in 
immunosuppressive conditions and cause diseases such as nephropathy and progressive 
multifocal leukoencephalopathy, respectively (Delbue, Comar & Ferrante 2012).  
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Several case studies have reported spontaneous regressions of MCCs that are likely immune 
cell-mediated (Inoue et al. 2000, Burack, Altschuler 2003, Burack, Altschuler 2003, 
Herrmann et al. 2004, Herrmann et al. 2004, Kubo et al. 2007, Richetta et al. 2008, Vesely 
et  al.  2008,  Turk  et  al.  2009,  Ciudad  et  al.  2010).  In  one  study,  peripherial  blood  
mononuclear cells drawn from MCPyV-seropositive healthy adults showed significantly 
stronger CD4+ cell responses than in samples of seronegative subjects when stimulated 
MCPyV VP1 virus-like particles (Kumar et al. 2011). Cell proliferation increased and 
especially secretion of interferon-?, an antiviral and tumor suppressing cytokine 
strengthened (Kumar et al. 2011). Therefore, drugs boosting the immune system might be 
beneficial in treatment of MCC. However, the interplay between the immune cell types is 
complex, and better understanding of the UV-related and age-related changes in the immune 
cell defense in the skin is necessary. For example, studies in mice have shown that UV 
irradiation enhances the genesis of suppressor T lymphocytes in the lymphoid organs and 
that these cells may support tumor growth (Fisher, Kripke 1982). In mice immunized with 
tumor antigens UV irradiation activates CD4+/CD25+/FoxP3- T cells that can impair the 
anti-tumor immune responses of cytotoxic CD8+ T cells (Toda et al. 2011), and in the 
absence of CD4+ cells, UV irradiation does not have an immunosuppressive effect on the 
CD8+ cell activity (Krasteva et al. 2002). UV irradiation enhances also mast cell migration 
from the skin to the draining lymph nodes, where they probably activate immunosuppressive 
B cells, and blocking of the UV-induced mast cell migration prevents immunosuppression in 
the skin of mice (Byrne, Limon-Flores & Ullrich 2008). We found that MCC patients whose 
CD8+  to  CD4+  or  FoxP3+  to  CD4+  cell  ratios  were  low  had  poorer  survival  than  patients  
with high ratios, suggesting that the treatments aiming at immune cell activation should be 
selective.  
 
Elderly people may have decreased immune function in the skin predisposing to cutaneous 
infections and malignancies. The impaired immunity in old people likely results from many 
alterations, such as reduced production of cytokines, impaired immune cell function, 
changes in the balance between different immune cell types and exhaustion of cytotoxic T 
cells (reviewed in Vukmanovic-Stejic et al. 2011). MCPyV occurs latently in the majority of 
humans, and repeated antigen stimulations through of the life and during tumor growth 
might cause exhaustion of MCPyV-specific cytotoxic T cells and reduced functional activity. 
Exhausted CD8+ cells have been found in many chronic viral infections, such as lymphocytic 
choriomeningitis virus infections (Barber et al. 2006) and hepatitis B infections in mice 
(Tzeng  et  al.  2012),  and  HIV  (Day  et  al.  2006),  and  hepatitis  B  and  C  virus  infections  in  
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humans (Urbani et al. 2006, Boni et al. 2007). CD8+ cell exhaustion in a chronic infection is 
regulated by multiple inhibitory receptors, the coexpression of which synergistically 
increases the severity of T cell exhaustion and infection (Blackburn et al. 2009). One such 
receptor is the programmed cell death 1 (PD-1), and inhibition of its ligand (PD ligand 1, PD-
L1) by an antibody restores the ability of CD8+ cells to proliferate, secrete cytokines, kill 
infected cells and diminish the viral load in chronically infected mice (Barber et al. 2006, 
Blackburn et al. 2009). An anti-PD-L1 antibody produced durable tumor regression and 
prolonged stabilization of cancer in patients with advanced melanoma, non-small cell lung 
carcinoma and renal cell carcinoma in a recent clinical trial (Brahmer et al. 2012). 
Hypothetically, cytotoxic T cell activation might be effective also in MCC, in which CD8+ cell 
function is likely to be of clinical relevance. 
 
3. Study limitations 
 
Selection  bias  is  a  potential  limitation  of  the  current  study.  Up  to  58.0%  (study  IV)  of  the  
samples were excluded from analysis for various reasons, such as unavailability of clinical 
data or tumor tissue samples. However, we did not find statistically significant differences 
between the patients who were included and those who were excluded from the study in 
median age at time of diagnosis, gender distribution or survival times (study I) suggesting 
that exclusion did not bring about major bias. Since the current series were a population-
based series unlike those in the other corresponding studies that we are aware of, selection 
bias may remain relatively limited in the current study.  
 
The gender distribution in the present series, which differs from that of some others, could 
also have impacted the results. Yet, a predominance of females has been reported also in 
some other MCC series (Laude et al.  2010, Andres et al.  2009, Handschel et al.  2010), and 
the association between presence of MCPyV in MCC and favorable survival has been 
reported also in series with a male predominance (Bhatia et al. 2010a, Nardi et al. 2012).  
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Due to the rarity of MCC, the present series remains numerically small despite being 
probably the second largest clinical series on MCC published thus far. Therefore, we may not 
have been able to detect some weak, but yet important associations between the parameters 
studied due to lacking statistical power (type II error). On the other hand, we may have 
found significant associations that occurred by chance (type I error), and repeat studies are 
warranted to confirm many of the results in other patient populations. It is possible that not 
all results we obtained in a Finnish patient population can be generalized to other patient 
populations.  
 
The type of tumor tissue used in this thesis work material may also have influenced the 
results. Formalin-fixed paraffin-embedded tissue samples contain fragmented DNA, which 
might hinder MCPyV DNA detection by qPCR in some cases. A primer set for another 
conserved MCPyV genome region might help to verify our results. However, the associations 
between the presence of MCPyV DNA, LT antigen and RB expression were strong, indicating 
that both quantitative PCR and immunohistochemistry can identify the majority of virus-
positive tumors and that the number of false negative results might be low. Tissue fixation 
also influences antigen preservation and, the results of immunohistochemistry. However, we 
found TP53 mutations to be associated with p53 expression, and the presence of MCPyV 
DNA, LT antigen and RB expression. In addition, we earlier verified immunohistochemistry 
for the KIT protein to be reliable using mRNA in situ hybridization (Sihto et al. 2007).  
 
4. Future studies 
 
Because of the rarity of the disease, large clinical series of MCC are not generally available, 
and clinical trials are also challenging to conduct. Fortunately, the discovery of MCPyV, a 
new human cancer virus, generated substantial interest in MCC, and some molecular 
mechanisms related to MCC tumorigenesis have been revealed within a few years. Yet, 
further studies addressing the MCC microenvironment, cancer cell activation and cell 
signaling are needed both in MCPyV-positive and MCPyV-negative cancers to identify 
potential new therapeutic targets in this highly malignant disease. The methods to identify 
MCPyV in tumor cells vary between laboratories, affecting the sensitivity and specificity of 
virus detection, and, therefore, interlaboratory studies comparing the virus detection 
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methods are required to standardize the findings. Multinational studies to identify potential 
differences in MCC tumorigenesis and MCPyV incidence at the population level are also 
warranted. At present, only few large nationwide population-based tumor series are 
available, and collection of such series would be valuable. 
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CONCLUSIONS 
 
The aim of this thesis work was to study MCC with respect to 1) the frequency of 
intratumoral MCPyV and its association with patient and tumor characteristics, disease 
outcome and cell cycle regulatory protein expression, 2) the presence of TP53, KIT and 
PDGFRA gene mutations and their protein expression and their associations with the 
presence of MCPyV, patient and tumor characteristics and survival, and 3) the frequency and 
type of tumor infiltrating immune cells, and their association with MCPyV, 
clinicopathological factors and disease outcome.  
The main conclusions are the following: 
1.     MCPyV  DNA  and  LT  antigen  were  found  in  the  majority  of  MCCs.  Tumors  that  
harbor MCPyV DNA usually expressed the viral LT antigen. 
2.    Patients whose MCC tumor cells express the viral LT antigen or contain MCPyV DNA 
in general have more favorable survival than patients whose tumor is LT-negative or 
MCPyV DNA-negative. 
3.    MCPyV LT expression was seen often in females, in tumors with intermediate cell 
type and in MCCs that arise in the limbs compared to those that arise in the trunk or 
in the head and neck region.  
4.    LT-positive MCCs generally showed a lower cell proliferation rate than LT-negative 
tumors. LT-positive MCCs expressed frequently the retinoblastoma protein and 
harbored rarely TP53, KIT or PDGFRA mutations, whereas KIT and p53 expression 
and TP53 mutations were found more often in LT-negative tumors.  
5.   The numbers of tumor infiltrating CD3+, CD8+, CD16+, FoxP3+ and CD68+ cells 
were higher in MCPyV DNA-positive MCCs than in MCPyV DNA-negative cancers, 
and patients  with a  high number of  CD3+,  CD8+ or  FoxP3+ lymphocytes  in  tumor 
had more favorable survival than patients with low numbers. A high tumor CD3+ cell 
count was an independent favorable prognostic factor in MCC suggesting that host 
defence influences survival of patients diagnosed with MCC. 
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Taken together, these findings suggest that the outcome of MCC patients is influenced by 
several molecular mechanisms where MCPyV infection, different cell signaling routes and 
the host immune response may all be involved. Further studies on these mechanisms may 
lead to new therapeutic approaches, such as vaccinations of selected risk groups or use of 
novel immunomodulatory agents.  
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